

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 28 May 2001 (28.05.01)	
International application No. PCT/EP00/09034	Applicant's or agent's file reference FB/BM45414
International filing date (day/month/year) 14 September 2000 (14.09.00)	Priority date (day/month/year) 14 September 1999 (14.09.99)
Applicant THONNARD, Joelle	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

11 April 2001 (11.04.01)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Claudio Borton
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

PRIVETT, Kathryn Louise
SmithKline Beecham
Corporate Intellectual Property
(CN9.25.1)
980 Great West Road
Brentford, Middlesex TW8 9GS
ROYAUME-UNI

Date of mailing (day/month/year) 08 February 2002 (08.02.02)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference FB/BM45414	
International application No. PCT/EP00/09034	International filing date (day/month/year) 14 September 2000 (14.09.00)

1. The following indications appeared on record concerning:		
<input type="checkbox"/> the applicant	<input type="checkbox"/> the inventor	<input checked="" type="checkbox"/> the agent
<input type="checkbox"/> the common representative		
Name and Address PRIVETT, Kathryn Louise SmithKline Beecham Two New Horizons Court Brentford Middlesex TW8 9EP United Kingdom	State of Nationality	State of Residence
	Telephone No. +44 20 8975 2585	
	Facsimile No. +44 20 8975 6294	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input type="checkbox"/> the person	<input type="checkbox"/> the name	<input checked="" type="checkbox"/> the address
<input type="checkbox"/> the nationality		
<input type="checkbox"/> the residence		
Name and Address PRIVETT, Kathryn Louise SmithKline Beecham Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS United Kingdom	State of Nationality	State of Residence
	Telephone No. +44 20 8047 5000	
	Facsimile No. +44 20 8047 6894	
	Teleprinter No.	
3. Further observations, if necessary: Please note that address of agent chapter II has been changed too.		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Alexandre BOUVIER Telephone No.: (41-22) 338.83.38
--	---

INTERNATIONAL SEARCH REPORT

International Application No
PL/EP 00/09034

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/22 C07K16/12 C12N1/21 C12N15/31 A61K38/16
A61K39/40 G01N33/569

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 41731 A (ANTEX BIOLOGICS, INC.) 13 November 1997 (1997-11-13) the whole document ---	1-26
A	WO 98 06851 A (BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEM) 19 February 1998 (1998-02-19) the whole document --- -/--	1-26

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

13 March 2001

Date of mailing of the international search report

02. 5. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fuchs, U

INTERNATIONAL SEARCH REPORT

International Application No
PLI/EP 00/09034

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EMBL database, Heidelberg, FRG Trembl accession number Q99116 1 November 1996 MAIDEN, M.C.J. ET AL.: "MAJOR OUTER MEMBRANE PROTEIN P.IA (PROTEIN IA) (PIA) (FRAGMENT)" XP002162771 the whole document	1-26
A	-& MAIDEN, M.C.J. ET AL.: "Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis" MOLECULAR MICROBIOLOGY, vol. 5, no. 3, March 1991 (1991-03), pages 727-736, XP000926232 the whole document -----	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 00/09034

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-26 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-26 partially

An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence SEQ ID NO: 2 over the entire length, an isolated polypeptide of SEQ ID NO: 2, an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence SEQ ID NO: 2 over the entire length or a nucleotide sequence complementary to said polynucleotide, an isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO: 2 over the entire coding region or a nucleotide sequence complementary to said polynucleotide, an isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO: 1 over the entire length or a nucleotide sequence complementary to said polynucleotide, an isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO: 2, an isolated polynucleotide comprising the polynucleotide of SEQ ID NO: 1, an expression vector or a recombinant live microorganism comprising said polynucleotide, a process for producing said polypeptide, a vaccine composition comprising said polypeptide or said polynucleotide, an antibody immunospecific for said polypeptide, a method of diagnosing a *M. catarrhalis* infection involving said polypeptide or said antibody, use of a composition comprising said polypeptide or said polynucleotide in the preparation of a medicament for immunization, a therapeutic composition comprising at least one antibody directed against said polypeptide;

2. Claims: 1-26 partially

Idem as subject 1 but limited to SEQ ID NOS: 3 and 4;

3. Claims: 1-26 partially

Idem as subject 1 but limited to SEQ ID NOS: 5 and 6.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/09034

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9741731 A	13-11-1997	AU 723528 B	31-08-2000
		AU 3118097 A	26-11-1997
		BG 102983 A	31-05-2000
		BR 9711090 A	17-08-1999
		CZ 9803524 A	16-06-1999
		EP 0900025 A	10-03-1999
		JP 2000510696 T	22-08-2000
		NO 985113 A	28-12-1998
		PL 330935 A	07-06-1999
		SK 150998 A	07-05-1999
		US 6214981 B	10-04-2001
WO 9806851 A	19-02-1998	AU 4150097 A	06-03-1998
		EP 0920513 A	09-06-1999



PATENT COOPERATION TREATY

by fax and post

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

To:

LUBIENSKI, Michael John et al
SMITHKLINE BEECHAM PLC
Two New Horizons Court
Brentford
Middlesex TW8 9EP
GRANDE BRETAGNE

RECEIVED

26 OCT 2001

NEW HORIZONS COURT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

Date of mailing
(day/month/year)

04.10.2001

Applicant's or agent's file reference
FB/BM45414

IMPORTANT NOTIFICATION

International application No.
PCT/EP00/09034

International filing date (day/month/year)
14/09/2000

Priority date (day/month/year)
14/09/1999

Applicant

SMITHKLINE BEECHAM BIOLOGICALS S.A. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Guerin, A

Tel. +49 89 2399-8061



PATENT COOPERATION TREATY

PCT



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference FB/BM45414	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP00/09034	International filing date (day/month/year) 14/09/2000	Priority date (day/month/year) 14/09/1999
International Patent Classification (IPC) or national classification and IPC C07K14/22		
Applicant SMITHKLINE BEECHAM BIOLOGICALS S.A. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 6 sheets, including this cover sheet.
- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
- These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:
- I ☒ Basis of the report
 - II ☐ Priority
 - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV ☐ Lack of unity of invention
 - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI ☒ Certain documents cited
 - VII ☐ Certain defects in the international application
 - VIII ☒ Certain observations on the international application

Date of submission of the demand 11/04/2001	Date of completion of this report 04.10.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Ury, A Tel phone N . +49 89 2399 8411 <div style="text-align: right;">  </div>

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/09034

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17):*)

Description, pages:

1-69 as originally filed

Claims, No.:

1-26 as originally filed

Sequence listing part of the description, pages:

1-6, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/09034

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 1-26 (partially).

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 1-26 (partially).

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Y s: Claims 1-14, 17-26

 No: Claims 15, 16

Inventive step (IS) Yes: Claims 1-14, 17-26

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/09034

	No:	Claims	15, 16
Industrial applicability (IA)	Yes:	Claims	1-26
	No:	Claims	

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet



Item V.

- I) The present invention relates to polypeptides and polynucleotides corresponding to the BASB129 gene and having the nucleotide and amino acid sequences set out in SEQ ID NO:1 and SEQ ID NO:2, respectively.
These sequences are from *Moraxella catarrhalis* strain ATCC 43617.
The BASB129 protein is present at the surface of *Moraxella catarrhalis* cells (Example 6).
A BASB129 vaccine has been shown to be efficient in enhancing lung clearance of *Moraxella catarrhalis* in mice (Example 10).
- II) None of the available documents cited in the ISR seem to be prejudicial to novelty and inventive step (Article 33.2 and 3 PCT) of the main object of the present set of claims.
- III) However the following objections arise. The BASB129 protein being present at the surface of *Moraxella catarrhalis* cells, naturally occurring *Moraxella catarrhalis* cells fall within the scope of claim 15 (the recombinant live microorganism can be a naturally occurring *Moraxella catarrhalis* cells; the word "recombinant" does not confer any distinguishing feature to the microorganism) and claim 16 (a naturally occurring *Moraxella catarrhalis* cells is a "host" cell comprising a subcellular fraction and/or a membrane of said host cell expressing the peptide of the invention).
Claims 15 and 16 therefore lack novelty under Article 33.2 PCT.

Item VI.

Certain published documents (Rule 70.10)

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 00/78968	28.12.00	16.06.00	18.06.99



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/09034

Item VIII.

The term "fragment thereof" used in claim 14 is vague and unclear and leaves the reader in doubt as to the meaning of the technical features to which it refers, thereby rendering the definition of the subject-matter of said claim unclear (Article 6 PCT).

4
2
4

•

PCT COOPERATION TREATY

PCT

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

ON DATABASE

To:

PRIVETT, Kathryn, Louise
SmithKline Beecham
Two New Horizons Court
Brentford
Middlesex TW8 9EP
ROYAUME-UNI

5 APR 2001

PCM

SOURCE M

RECEIVED

30 MAR 2001

NEW HORIZONS COURT

Date of mailing (day/month/year) 22 March 2001 (22.03.01)		
Applicant's or agent's file reference FB/BM45414		IMPORTANT NOTICE
International application No. PCT/EP00/09034	International filing date (day/month/year) 14 September 2000 (14.09.00)	Priority date (day/month/year) 14 September 1999 (14.09.99)
Applicant SMITHKLINE BEECHAM BIOLOGICALS S.A. et al		

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:
AU,KP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:
AE,AG,AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,BZ,CA,CH,CN,CR,CU,CZ,DE,DK,DM,DZ,EA,EE,EP,ES,FI,GB,GD,GE,GH,GM,HR,HU,ID,IL,IN,IS,JP,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MA,MD,MG,MK,MN,MW,MX,MZ,NO,NZ,OA,PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,TZ,UA,UG,UZ,VN,YU,
The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).
3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on
22 March 2001 (22.03.01) under No. WO 01/19862

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 740.14.35	Authorized officer J. Zahra Tel phone No. (41-22) 338.83.38
--	---

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19862 A2

(51) International Patent Classification⁷: C07K 14/22,
16/12, C12N 1/21, 15/31, A61K 38/16, 39/40, G01N
33/569

(74) Agent: **PRIVETT, Kathryn, Louise**; SmithKline
Beecham, Two New Horizons Court, Brentford, Middlesex
TW8 9EP (GB).

(21) International Application Number: PCT/EP00/09034

(22) International Filing Date:
14 September 2000 (14.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9921694.7 14 September 1999 (14.09.1999) GB
9921693.9 14 September 1999 (14.09.1999) GB
9922829.8 25 September 1999 (25.09.1999) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM BIOLOGICALS S.A.
[BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

Published:

— *Without international search report and to be republished
upon receipt of that report.*

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **THONNARD, Joelle**
[BE/BE]; SmithKline Beecham Biologicals s.a., Rue de
L'Institut 89, B-1330 Rixensart (BE).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL COMPOUNDS

(57) Abstract: The invention provides BASB129, BASB130 and BASB131 polypeptides and polynucleotides encoding BASB129, BASB130 and BASB131 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

WO 01/19862 A2

Novel Compounds

FIELD OF THE INVENTION

This invention relates to polynucleotides, (herein referred to as "BASB129, BASB130 or BASB131 polynucleotide(s)"), polypeptides encoded by them (referred to herein as "BASB129, BASB130 or BASB131" or "BASB129, BASB130 or BASB131 polypeptide(s)"), recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including vaccines against bacterial infections. In a further aspect, the invention relates to diagnostic assays for detecting infection of certain pathogens.

BACKGROUND OF THE INVENTION

Moraxella catarrhalis (also named *Branhamella catarrhalis*) is a Gram negative bacteria frequently isolated from the human upper respiratory tract. It is responsible for several pathologies the main ones being otitis media in infants and children, and pneumonia in elderly. It is also responsible of sinusitis, nosocomial infections and less frequently of invasive diseases.

Otitis media is an important childhood disease both by the number of cases and its potential sequelae. More than 3.5 millions cases are recorded every year in the United States, and it is estimated that 80 % of the children have experienced at least one episode of otitis before reaching the age of 3 (Klein, JO (1994) Clin.Inf.Dis 19:823). Left untreated, or becoming chronic, this disease may lead to hearing losses that could be temporary (in the case of fluid accumulation in the middle ear) or permanent (if the auditive nerve is damaged). In infants, such hearing losses may be responsible for a delayed speech learning.

Three bacterial species are primarily isolated from the middle ear of children with otitis media: *Streptococcus pneumoniae*, non typeable *Haemophilus influenza* (NTHi) and *M. catarrhalis*. They are present in 60 to 90 % of the cases. A review of recent studies shows

that *S. pneumoniae* and NTHi represent both about 30 %, and *M. catarrhalis* about 15 % of the otitis media cases (Murphy, TF (1996) Microbiol.Rev. 60:267). Other bacteria could be isolated from the middle ear (*H. influenza* type B, *S. pyogenes* etc) but at a much lower frequency (2 % of the cases or less).

Epidemiological data indicate that, for the pathogens found in the middle ear, the colonization of the upper respiratory tract is an absolute prerequisite for the development of an otitis; other are however also required to lead to the disease (Dickinson, DP et al. (1988) J. Infect.Dis. 158:205, Faden, HL et al. (1991) Ann.Otorhinol.Laryngol. 100:612). These are important to trigger the migration of the bacteria into the middle ear via the Eustachian tubes, followed by the initiation of an inflammatory process. These factors are unknown todate. It has been postulated that a transient anomaly of the immune system following a viral infection, for example, could cause an inability to control the colonization of the respiratory tract (Faden, HL et al (1994) J. Infect.Dis. 169:1312). An alternative explanation is that the exposure to environmental factors allow a more important colonization of some children, who subsequently become susceptible to the development of otitis media because of the sustained presence of middle ear pathogens (Murphy, TF (1996) Microbiol.Rev. 60:267).

The immune response to *M. catarrhalis* is poorly characterized. The analysis of strains isolated sequentially from the nasopharynx of babies followed from 0 to 2 years of age, indicates that they get and eliminate frequently new strains. This indicates that an efficacious immune response against this bacteria is mounted by the colonized children (Faden, HL et al (1994) J. Infect.Dis. 169:1312).

In most adults tested, bactericidal antibodies have been identified (Chapman, AJ et al. (1985) J. Infect.Dis. 151:878). Strains of *M. catarrhalis* present variations in their capacity to resist serum bactericidal activity: in general, isolates from diseased individuals are more resistant than those who are simply colonized (Hol, C et al. (1993) Lancet 341:1281, Jordan,

KL et al. (1990) Am.J.Med. 88 (suppl. 5A):28S). Serum resistance could therefore be considered as a virulence factor of the bacteria. An opsonizing activity has been observed in the sera of children recovering from otitis media.

The antigens targetted by these different immune responses in humans have not been identified, with the exception of OMP B1, a 84 kDa protein which expression is regulated by iron, and that is recognized by the sera of patients with pneumonia (Sethi, S, et al. (1995) Infect.Immun. 63:1516) , and of UspA1 and UspA2 (Chen D. et al.(1999), Infect.Immun. 67:1310).

A few other membrane proteins present on the surface of *M. catarrhalis* have been characterized using biochemical method, or for their potential implication in the induction of a protective immunity (for review, see Murphy, TF (1996) Microbiol.Rev. 60:267). In a mouse pneumonia model, the presence of antibodies raised against some of them (UspA, CopB) favors a faster clearance of the pulmonary infection. Another polypeptide (OMP CD) is highly conserved among *M. catarrhalis* strains, and presents homologies with a porin of *Pseudomonas aeruginosa*, which has been demonstrated efficacious against this bacterium in animal models.

The frequency of *Moraxella catarrhalis* infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate *Moraxella catarrhalis* strains that are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism.

SUMMARY OF THE INVENTION

The present invention relates to BASB1298, BASB130 and BASB131, in particular BASB129, BASB130 and BASB131 polypeptides and BASB129, BASB130 and BASB131 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including prevention and treatment of microbial diseases, amongst others. In a further aspect, the invention relates to diagnostic assays for detecting diseases associated with microbial infections and conditions associated with such infections, such as assays for detecting expression or activity of BASB129, BASB130 and BASB131 polynucleotides or polypeptides.

Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

The invention relates to BASB129, BASB130 and BASB131 polypeptides and polynucleotides as described in greater detail below.

In particular, the invention relates to polypeptides and polynucleotides of BASB129 of *Moraxella catarrhalis*, which is related by amino acid sequence homology to *Haemophilus influenzae* major outer membrane protein P2. The invention relates especially to BASB129 having the nucleotide and amino acid sequences set out in SEQ ID NO:1 and SEQ ID NO:2 respectively.

In particular, the invention also relates to polypeptides and polynucleotides of BASB130 of *Moraxella catarrhalis*, which is related by amino acid sequence homology to *Bordetella pertussis* hemolysin activator-like protein FhaC. The invention relates especially to BASB130 having the nucleotide and amino acid sequences set out in SEQ ID NO:3 and SEQ ID NO:4 respectively.

In particular, the invention also relates to polypeptides and polynucleotides of BASB131 of *Moraxella catarrhalis*, which is related by amino acid sequence homology to a lipase-

like protein of *Helicobacter pylori* and CyaE of *Bordetella pertusis*. The invention relates especially to BASB131 having the nucleotide and amino acid sequences set out in SEQ ID NO:5 and SEQ ID NO:6 respectively.

It is understood that sequences recited in the Sequence Listing below as "DNA" represent an exemplification of one embodiment of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.

Polypeptides

In one aspect of the invention there are provided polypeptides of *Moraxella catarrhalis* referred to herein as "BASB129, BASB130 and BASB131" and "BASB129, BASB130 and BASB131 polypeptides" as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:2, 4 or 6;
- (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1, 3 or 5 over the entire length of SEQ ID NO:1, 3 or 5 respectively; or
- (c) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO:2, 4 or 6.

The BASB129, BASB130 and BASB131 polypeptides provided in SEQ ID NO:2, 4 or 6 are the BASB129, BASB130 and BASB131 polypeptides from *Moraxella catarrhalis* strain Mc2931 (ATCC 43617).

The invention also provides an immunogenic fragment of a BASB129, BASB130 and BASB131 polypeptide, that is, a contiguous portion of the BASB129, BASB130 and BASB131 polypeptide which has the same or substantially the same immunogenic activity as the polypeptide comprising the amino acid sequence of SEQ ID NO:2, 4 or 6; That is to say, the fragment (if necessary when coupled to a carrier) is capable of raising an immune response which recognises the BASB129, BASB130 and BASB131 polypeptide. Such an immunogenic fragment may include, for example, the BASB129, BASB130 and BASB131 polypeptide lacking an N-terminal leader sequence, and/or a transmembrane domain and/or a C-terminal anchor domain. In a preferred aspect the immunogenic fragment of BASB129, BASB130 and BASB131 according to the invention comprises substantially all of the extracellular domain of a polypeptide which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2, 4 or 6 over the entire length of SEQ ID NO:2, 4 or 6 respectively.

A fragment is a polypeptide having an amino acid sequence that is entirely the same as part but not all of any amino acid sequence of any polypeptide of the invention. As with BASB129, BASB130 and BASB131 polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region in a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence of SEQ ID NO:2, 4 or 6 or of variants thereof, such as a continuous series of residues that includes an amino- and/or carboxyl-terminal amino acid sequence. Degradation forms of the polypeptides of the invention produced by or in a host cell, are

also preferred. Further preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Further preferred fragments include an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:2, 4 or 6, or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO:2, 4 or 6.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these fragments may be employed as intermediates for producing the full-length polypeptides of the invention.

Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

The polypeptides, or immunogenic fragments, of the invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production. Furthermore, addition of exogenous polypeptide or lipid tail or polynucleotide sequences to increase the immunogenic potential of the final molecule is also considered.

In one aspect, the invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa.

Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

The proteins may be chemically conjugated, or expressed as recombinant fusion proteins allowing increased levels to be produced in an expression system as compared to non-fused protein. The fusion partner may assist in providing T helper epitopes (immunological fusion partner), preferably T helper epitopes recognised by humans, or assist in expressing the protein (expression enhancer) at higher yields than the native recombinant protein. Preferably the fusion partner will be both an immunological fusion partner and expression enhancing partner.

Fusion partners include protein D from *Haemophilus influenzae* and the non-structural protein from influenzae virus, NS1 (hemagglutinin). Another fusion partner is the protein known as LytA. Preferably the C terminal portion of the molecule is used. LytA is derived from *Streptococcus pneumoniae* which synthesize an N-acetyl-L-alanine amidase, amidase LytA, (coded by the lytA gene {Gene, 43 (1986) page 265-272}) an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The

C-terminal domain of the LytA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E.coli C-LytA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LytA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 795-798}. It is possible to use the repeat portion of the LytA molecule found in the C terminal end starting at residue 178, for example residues 188 - 305.

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.

Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

It is most preferred that a polypeptide of the invention is derived from *Moraxella catarrhalis*, however, it may preferably be obtained from other organisms of the same taxonomic genus. A polypeptide of the invention may also be obtained, for example, from organisms of the same taxonomic family or order.

Polynucleotides

It is an object of the invention to provide polynucleotides that encode BASB129, BASB130 and BASB131 polypeptides, particularly polynucleotides that encode the polypeptide herein designated BASB129, BASB130 and BASB131.

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding BASB129, BASB130 and BASB131 polypeptides comprising a sequence set out in SEQ ID NO:1, 3 or 5 which includes a full length gene, or a variant thereof.

The BASB129, BASB130 and BASB131 polynucleotides provided in SEQ ID NO:1, 3 or 5 are the BASB129, BASB130 and BASB131 polynucleotides from *Moraxella catarrhalis* strain Mc2931 (ATCC 43617).

As a further aspect of the invention there are provided isolated nucleic acid molecules encoding and/or expressing BASB129, BASB130 and BASB131 polypeptides and polynucleotides, particularly *Moraxella catarrhalis* BASB129, BASB130 and BASB131 polypeptides and polynucleotides, including, for example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.

Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a BASB129, BASB130 and BASB131 polypeptide having a deduced amino acid sequence of SEQ ID NO:2, 4 or 6 and polynucleotides closely related thereto and variants thereof.

In another particularly preferred embodiment of the invention there is a BASB129, BASB130 and BASB131 polypeptide from *Moraxella catarrhalis* comprising or consisting of an amino acid sequence of SEQ ID NO:2, 4 or 6 or a variant thereof.

Using the information provided herein, such as a polynucleotide sequence set out in SEQ ID NO:1, 3 or 5, a polynucleotide of the invention encoding BASB129, BASB130 and BASB131 polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Moraxella catarrhalis* Catlin cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a polynucleotide sequence given in SEQ ID NO:1, 3 or 5, typically a library of clones of chromosomal DNA of *Moraxella catarrhalis* Catlin in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By sequencing the individual clones thus identified by hybridization with sequencing primers designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of the invention, each polynucleotide set out in SEQ ID NO:1, 3 or 5 was discovered in a DNA library derived from *Moraxella catarrhalis*.

Moreover, each DNA sequence set out in SEQ ID NO:1, 3 or 5 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ ID NO:2, 4 or 6 with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known to those skilled in the art.

The polynucleotide of SEQ ID NO:1, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 1033 of SEQ ID NO:1, encodes the polypeptide of SEQ ID NO:2.

The polynucleotide of SEQ ID NO:3, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 2035 of SEQ ID NO:3, encodes the polypeptide of SEQ ID NO:4.

The polynucleotide of SEQ ID NO:5, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 1408 of SEQ ID NO:5, encodes the polypeptide of SEQ ID NO:6.

In a further aspect, the present invention provides for an isolated polynucleotide comprising or consisting of:

- (a) a polynucleotide sequence which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1, 3 or 5 over the entire length of SEQ ID NO:1, 3 or 5 respectively; or
- (b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, preferably at least 90% identity, more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of SEQ ID NO:2, 4 or 6, over the entire length of SEQ ID NO:2, 4 or 6 respectively.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than *Moraxella catarrhalis*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising the sequence of SEQ ID NO:1, 3 or 5 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

The invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) in SEQ ID NO:1, 3 or 5. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals. The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA peptide tag (Wilson *et al.*, *Cell* 37: 767 (1984), both of which may be useful in purifying polypeptide sequence fused to them. Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

The nucleotide sequence encoding BASB129, BASB130 and BASB131 polypeptide of SEQ ID NO:2, 4 or 6 may be identical to the polypeptide encoding sequence contained in nucleotides 1 to 1033 of SEQ ID NO:1 or the polypeptide encoding sequence contained in nucleotides 1 to 2035 of SEQ ID NO:3 or the polypeptide encoding sequence contained in nucleotides 1 to 1408 of SEQ ID NO:5 respectively. Alternatively the nucleotide sequence encoding BASB129, BASB130 and BASB131 may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of

SEQ ID NO:2, 4 or 6.

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Moraxella catarrhalis* BASB129, BASB130 and BASB131 having an amino acid sequence set out in SEQ ID NO:2, 4 or 6. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may contain coding and/or non-coding sequences.

The invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of SEQ ID NO:2, 4 or 6. Fragments of polynucleotides of the invention may be used, for example, to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB129, BASB130 and BASB131 variants, that have the amino acid sequence of BASB129, BASB130 and BASB131 polypeptide of SEQ ID NO:2, 4 or 6 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of BASB129, BASB130 and BASB131 polypeptide.

Further preferred embodiments of the invention are polynucleotides that are at least 85% identical over their entire length to a polynucleotide encoding BASB129, BASB130 and BASB131 polypeptide having an amino acid sequence set out in SEQ ID NO:2, 4 or 6, and

polynucleotides that are complementary to such polynucleotides. Alternatively, most highly preferred are polynucleotides that comprise a region that is at least 90% identical over its entire length to a polynucleotide encoding BASB129, BASB130 and BASB131 polypeptide and polynucleotides complementary thereto. In this regard, polynucleotides at least 95% identical over their entire length to the same are particularly preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of SEQ ID NO:1, 3 or 5.

In accordance with certain preferred embodiments of this invention there are provided polynucleotides that hybridize, particularly under stringent conditions, to BASB129, BASB130 and BASB131 polynucleotide sequences, such as those polynucleotides in SEQ ID NO:1, 3 or 5.

The invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization occurring only if there is at least 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*,

Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.

The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:1, 3 or 5 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:1, 3 or 5 or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB129, BASB130 and BASB131 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB129, BASB130 and BASB131 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

A coding region of a BASB129, BASB130 and BASB131 gene may be isolated by screening using a DNA sequence provided in SEQ ID NO:1, 3 or 5 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

There are several methods available and well known to those skilled in the art to obtain full-length DNAs, or extend short DNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman, *et al.*, *PNAS USA* 85: 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the DNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using "nested" primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the selected gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length DNA constructed either by joining the product directly to the existing DNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for diseases, particularly human diseases, as further discussed herein relating to polynucleotide assays.

The polynucleotides of the invention that are oligonucleotides derived from a sequence of SEQ ID NO:1, 3 or 5 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

The invention also provides polynucleotides that encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

For each and every polynucleotide of the invention there is provided a polynucleotide complementary to it. It is preferred that these complementary polynucleotides are fully complementary to each polynucleotide with which they are complementary.

A precursor protein, having a mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In addition to the standard A, G, C, T/U representations for nucleotides, the term "N" may also be used in describing certain polynucleotides of the invention. "N" means that any of the four DNA or RNA nucleotides may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a nucleic acid that when taken in combination with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon in such reading frame.

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a proproprotein, which is a precursor to a proprotein, having a leader sequence and one or

more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

In accordance with an aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff *et al.*, *Hum Mol Genet* (1992) 1: 363, Manthorpe *et al.*, *Hum. Gene Ther.* (1983) 4: 419), delivery of DNA complexed with specific protein carriers (Wu *et al.*, *J Biol Chem.* (1989) 264: 16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, *PNAS USA*, (1986) 83: 9551), encapsulation of DNA in various forms of liposomes (Kaneda *et al.*, *Science* (1989) 243: 375), particle bombardment (Tang *et al.*, *Nature* (1992) 356:152, Eisenbraun *et al.*, *DNA Cell Biol* (1993) 12: 791) and *in vivo* infection using cloned retroviral vectors (Seeger *et al.*, *PNAS USA* (1984) 81: 5849).

Vectors, Host Cells, Expression Systems

The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

Recombinant polypeptides of the present invention may be prepared by processes well known in those skilled in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems that comprise a polynucleotide or polynucleotides of the present

invention, to host cells which are genetically engineered with such expression systems, and to the production of polypeptides of the invention by recombinant techniques.

For recombinant production of the polypeptides of the invention, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis, *et al.*, *BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook, *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

Representative examples of appropriate hosts include bacterial cells, such as cells of streptococci, staphylococci, enterococci, *E. coli*, streptomyces, cyanobacteria, *Bacillus subtilis*, *Neisseria meningitidis* and *Moraxella catarrhalis*; fungal cells, such as cells of a yeast, *Kluveromyces*, *Saccharomyces*, a basidiomycete, *Candida albicans* and *Aspergillus*; insect cells such as cells of *Drosophila* S2 and *Spodoptera* Sf9; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293, CV-1 and Bowes melanoma cells; and plant cells, such as cells of a gymnosperm or angiosperm.

A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal-, episomal- and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, picornaviruses, retroviruses, and alphaviruses and vectors derived from combinations thereof, such as those derived from

plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL*, (*supra*).

In recombinant expression systems in eukaryotes, for secretion of a translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, ion metal affinity chromatography (IMAC) is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

The expression system may also be a recombinant live microorganism, such as a virus or bacterium. The gene of interest can be inserted into the genome of a live recombinant virus or bacterium. Inoculation and *in vivo* infection with this live vector will lead to *in vivo* expression of the antigen and induction of immune responses. Viruses and bacteria used for this purpose are for instance: poxviruses (e.g; vaccinia, fowlpox, canarypox), alphaviruses (Sindbis virus, Semliki Forest Virus, Venezuelan Equine Encephalitis

Virus), adenoviruses, adeno-associated virus, picornaviruses (poliovirus, rhinovirus), herpesviruses (varicella zoster virus, etc), Listeria, Salmonella, Shigella, BCG. These viruses and bacteria can be virulent, or attenuated in various ways in order to obtain live vaccines. Such live vaccines also form part of the invention.

Diagnostic, Prognostic, Serotyping and Mutation Assays

This invention is also related to the use of BASB129, BASB130 and BASB131 polynucleotides and polypeptides of the invention for use as diagnostic reagents. Detection of BASB129, BASB130 and BASB131 polynucleotides and/or polypeptides in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of disease, staging of disease or response of an infectious organism to drugs. Eukaryotes, particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism comprising the BASB129, BASB130 and BASB131 gene or protein, may be detected at the nucleic acid or amino acid level by a variety of well known techniques as well as by methods provided herein.

Polypeptides and polynucleotides for prognosis, diagnosis or other analysis may be obtained from a putatively infected and/or infected individual's bodily materials. Polynucleotides from any of these sources, particularly DNA or RNA, may be used directly for detection or may be amplified enzymatically by using PCR or any other amplification technique prior to analysis. RNA, particularly mRNA, cDNA and genomic DNA may also be used in the same ways. Using amplification, characterization of the species and strain of infectious or resident organism present in an individual, may be made by an analysis of the genotype of a selected polynucleotide of the organism. Deletions and insertions can be detected by a change in size of the amplified product in comparison to a genotype of a reference sequence selected from a related organism, preferably a different species of the same genus or a different strain of the same species. Point mutations can be identified by hybridizing amplified DNA to labeled BASB129, BASB130 and BASB131 polynucleotide sequences. Perfectly or significantly matched sequences can be distinguished from imperfectly or more

significantly mismatched duplexes by DNase or RNase digestion, for DNA or RNA respectively, or by detecting differences in melting temperatures or renaturation kinetics. Polynucleotide sequence differences may also be detected by alterations in the electrophoretic mobility of polynucleotide fragments in gels as compared to a reference sequence. This may be carried out with or without denaturing agents. Polynucleotide differences may also be detected by direct DNA or RNA sequencing. See, for example, Myers *et al.*, *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase, V1 and S1 protection assay or a chemical cleavage method. See, for example, Cotton *et al.*, *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).

In another embodiment, an array of oligonucleotide probes comprising BASB129, BASB130 and BASB131 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of, for example, genetic mutations, serotype, taxonomic classification or identification. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see, for example, Chee *et al.*, *Science*, 274: 610 (1996)).

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO:1, 3 or 5, or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2, 4 or 6 or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2, 4 or 6.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a Disease, among others.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of a polynucleotide of the invention, preferably SEQ ID NO:1, 3 or 5, which is associated with a disease or pathogenicity will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, a prognosis of a course of disease, a determination of a stage of disease, or a susceptibility to a disease, which results from under-expression, over-expression or altered expression of the polynucleotide. Organisms, particularly infectious organisms, carrying mutations in such polynucleotide may be detected at the polynucleotide level by a variety of techniques, such as those described elsewhere herein.

Cells from an organism carrying mutations or polymorphisms (allelic variations) in a polynucleotide and/or polypeptide of the invention may also be detected at the polynucleotide or polypeptide level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations in the RNA. It is particularly preferred to use RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA, cDNA or genomic DNA may also be used for the same purpose, PCR. As an example, PCR primers complementary to a polynucleotide encoding BASB129, BASB130 and BASB131 polypeptide can be used to identify and analyze mutations.

The invention further provides primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying BASB129, BASB130 and BASB131 DNA and/or RNA isolated from a sample derived from an individual, such as a bodily material. The primers may be used to amplify a polynucleotide isolated from an infected individual, such that the polynucleotide may then

be subject to various techniques for elucidation of the polynucleotide sequence. In this way, mutations in the polynucleotide sequence may be detected and used to diagnose and/or prognose the infection or its stage or course, or to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing, disease, preferably bacterial infections, more preferably infections caused by *Moraxella catarrhalis*, comprising determining from a sample derived from an individual, such as a bodily material, an increased level of expression of polynucleotide having a sequence of SEQ ID NO:1, 3 or 5. Increased or decreased expression of a BASB129, BASB130 and BASB131 polynucleotide can be measured using any one of the methods well known in the art for the quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting, spectrometry and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-expression of BASB129, BASB130 and BASB131 polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a BASB129, BASB130 and BASB131 polypeptide, in a sample derived from a host, such as a bodily material, are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis, antibody sandwich assays, antibody detection and ELISA assays.

The polynucleotides of the invention may be used as components of polynucleotide arrays, preferably high density arrays or grids. These high density arrays are particularly useful for diagnostic and prognostic purposes. For example, a set of spots each comprising a different gene, and further comprising a polynucleotide or polynucleotides of the invention, may be used for probing, such as using hybridization or nucleic acid amplification, using a probes obtained or derived from a bodily sample,

to determine the presence of a particular polynucleotide sequence or related sequence in an individual. Such a presence may indicate the presence of a pathogen, particularly *Moraxella catarrhalis*, and may be useful in diagnosing and/or prognosing disease or a course of disease. A grid comprising a number of variants of the polynucleotide sequence of SEQ ID NO:1, 3 or 5 are preferred. Also preferred is a comprising a number of variants of a polynucleotide sequence encoding the polypeptide sequence of SEQ ID NO:2, 4 or 6.

Antibodies

The polypeptides and polynucleotides of the invention or variants thereof, or cells expressing the same can be used as immunogens to produce antibodies immunospecific for such polypeptides or polynucleotides respectively. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

In certain preferred embodiments of the invention there are provided antibodies against BASB129, BASB130 and BASB131 polypeptides or polynucleotides.

Antibodies generated against the polypeptides or polynucleotides of the invention can be obtained by administering the polypeptides and/or polynucleotides of the invention, or epitope-bearing fragments of either or both, analogues of either or both, or cells expressing either or both, to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides or polynucleotides of this invention. Also, transgenic mice, or other organisms or animals, such as other mammals, may be used to express humanized antibodies immunospecific to the polypeptides or polynucleotides of the invention.

Alternatively, phage display technology may be utilized to select antibody genes with binding activities towards a polypeptide of the invention either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-BASB129, -BASB130 and -BASB131 or from naive libraries (McCafferty, *et al.*, (1990), *Nature* 348, 552-554; Marks, *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by, for example, chain shuffling (Clackson *et al.*, (1991) *Nature* 352: 628).

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides or polynucleotides of the invention to purify the polypeptides or polynucleotides by, for example, affinity chromatography.

Thus, among others, antibodies against BASB1029, BASB130 and BASB131-polypeptide or BASB129, BASB130 and BASB131-polynucleotide may be employed to treat infections, particularly bacterial infections.

Polypeptide variants include antigenically, epitopically or immunologically equivalent variants form a particular aspect of this invention.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized," where the complementarity determining region or regions of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as

described in Jones *et al.* (1986), *Nature* 321, 522-525 or Tempest *et al.*, (1991) *Biotechnology* 9, 266-273.

Antagonists and Agonists - Assays and Molecules

Polypeptides and polynucleotides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, *e.g.*, Coligan *et al.*, *Current Protocols in Immunology* 1(2): Chapter 5 (1991).

The screening methods may simply measure the binding of a candidate compound to the polypeptide or polynucleotide, or to cells or membranes bearing the polypeptide or polynucleotide, or a fusion protein of the polypeptide by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide or polynucleotide, using detection systems appropriate to the cells comprising the polypeptide or polynucleotide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptide and/or constitutively expressed polypeptides and polynucleotides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide or polynucleotide, as the case may be. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide or polynucleotide of the present invention, to form a mixture, measuring BASB129, BASB130 and BASB131 polypeptide and/or polynucleotide activity in the mixture, and comparing the BASB129, BASB130 and BASB131

polypeptide and/or polynucleotide activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and BASB129, BASB130 and BASB131 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of BASB129, BASB130 and BASB131 polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bactericidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising BASB129, BASB130 and BASB131 polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a BASB129, BASB130 and BASB131 agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the BASB129, BASB130 and BASB131 polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously,

i.e., without inducing the effects of BASB129, BASB130 and BASB131 polypeptide are most likely to be good antagonists. Molecules that bind well and, as the case may be, increase the rate of product production from substrate, increase signal transduction, or increase chemical channel activity are agonists. Detection of the rate or level of, as the case may be, production of product from substrate, signal transduction, or chemical channel activity may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric, labeled substrate converted into product, a reporter gene that is responsive to changes in BASB129, BASB130 and BASB131 polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for BASB129, BASB130 and BASB131 agonists is a competitive assay that combines BASB129, BASB130 and BASB131 and a potential agonist with BASB129, BASB130 and BASB131-binding molecules, recombinant BASB129, BASB130 and BASB131 binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. BASB129, BASB130 and BASB131 can be labeled, such as by radioactivity or a colorimetric compound, such that the number of BASB129, BASB130 and BASB131 molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include, among others, small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide and/or polypeptide of the invention and thereby inhibit or extinguish its activity or expression. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing BASB129, BASB130 and BASB131-induced activities, thereby preventing the action or expression of BASB129, BASB130 and BASB131 polypeptides and/or polynucleotides by excluding BASB129, BASB130 and BASB131 polypeptides and/or polynucleotides from binding.

Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, *J. Neurochem.* 56: 560 (1991); *OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION*, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of BASB129, BASB130 and BASB131.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

Each of the polynucleotide sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the polynucleotide sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno

or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The invention also provides the use of the polypeptide, polynucleotide, agonist or antagonist of the invention to interfere with the initial physical interaction between a pathogen or pathogens and a eukaryotic, preferably mammalian, host responsible for sequelae of infection. In particular, the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive and/or gram negative bacteria, to eukaryotic, preferably mammalian, extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block bacterial adhesion between eukaryotic, preferably mammalian, extracellular matrix proteins and bacterial BASB129, BASB130 and BASB131 proteins that mediate tissue damage and/or; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

In accordance with yet another aspect of the invention, there are provided BASB129, BASB130 and BASB131 agonists and antagonists, preferably bacteristatic or bactericidal agonists and antagonists.

The antagonists and agonists of the invention may be employed, for instance, to prevent, inhibit and/or treat diseases.

In a further aspect, the present invention relates to mimotopes of the polypeptide of the invention. A mimotope is a peptide sequence, sufficiently similar to the native peptide (sequentially or structurally), which is capable of being recognised by antibodies which recognise the native peptide; or is capable of raising antibodies which recognise the native peptide when coupled to a suitable carrier.

Peptide mimotopes may be designed for a particular purpose by addition, deletion or substitution of elected amino acids. Thus, the peptides may be modified for the purposes of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine. In addition it may be desirable for peptides conjugated to a protein carrier to include a hydrophobic terminus distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein. Thereby presenting the peptide in a conformation which most closely resembles that of the peptide as found in the context of the whole native molecule. For example, the peptides may be altered to have an N-terminal cysteine and a C-terminal hydrophobic amidated tail. Alternatively, the addition or substitution of a D-stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to enhance stability of the peptide.

Alternatively, peptide mimotopes may be identified using antibodies which are capable themselves of binding to the polypeptides of the present invention using techniques such as phage display technology (EP 0 552 267 B1). This technique, generates a large number of peptide sequences which mimic the structure of the native peptides and are, therefore, capable of binding to anti-native peptide antibodies, but may not necessarily themselves share significant sequence homology to the native polypeptide.

Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, preferably humans, which comprises inoculating the individual with BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly *Moraxella catarrhalis* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of

the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector, sequence or ribozyme to direct expression of BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide, or a fragment or a variant thereof, for expressing BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide, or a fragment or a variant thereof *in vivo* in order to induce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual, preferably a human, from disease, whether that disease is already established within the individual or not. One example of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a ribozyme, a modified nucleic acid, a DNA/RNA hybrid, a DNA-protein complex or an RNA-protein complex.

A further aspect of the invention relates to an immunological composition that when introduced into an individual, preferably a human, capable of having induced within it an immunological response, induces an immunological response in such individual to a BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide encoded therefrom, wherein the composition comprises a recombinant BASB129, BASB130 and BASB131 polynucleotide and/or polypeptide encoded therefrom and/or comprises DNA and/or RNA which encodes and expresses an antigen of said BASB129, BASB130 and BASB131 polynucleotide, polypeptide encoded therefrom, or other polypeptide of the invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity and/or cellular immunity, such as cellular immunity arising from CTL or CD4+ T cells.

A BASB129, BASB130 and BASB131 polypeptide or a fragment thereof may be fused with co-protein or chemical moiety which may or may not by itself produce antibodies, but which is capable of stabilizing the first protein and producing a fused or modified protein which will have antigenic and/or immunogenic properties, and preferably

protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from *Haemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, or any other relatively large co-protein which solubilizes the protein and facilitates production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system of the organism receiving the protein. The co-protein may be attached to either the amino- or carboxy-terminus of the first protein.

In a vaccine composition according to the invention, a BASB129, BASB130 and BASB131 polypeptide and/or polynucleotide, or a fragment, or a mimotope, or a variant thereof may be present in a vector, such as the live recombinant vectors described above for example live bacterial vectors.

Also suitable are non-live vectors for the BASB129, BASB130 and BASB131 polypeptide, for example bacterial outer-membrane vesicles or "blebs". OM blebs are derived from the outer membrane of the two-layer membrane of Gram-negative bacteria and have been documented in many Gram-negative bacteria (Zhou, L *et al.* 1998. *FEMS Microbiol. Lett.* 163:223-228) including *C. trachomatis* and *C. psittaci*. A non-exhaustive list of bacterial pathogens reported to produce blebs also includes: *Bordetella pertussis*, *Borrelia burgdorferi*, *Brucella melitensis*, *Brucella ovis*, *Escherichia coli*, *Haemophilus influenza*, *Legionella pneumophila*, *Moraxella catarrhalis*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas aeruginosa* and *Yersinia enterocolitica*.

Blebs have the advantage of providing outer-membrane proteins in their native conformation and are thus particularly useful for vaccines. Blebs can also be improved for vaccine use by engineering the bacterium so as to modify the expression of one or more molecules at the outer membrane. Thus for example the expression of a desired immunogenic protein at the outer membrane, such as the BASB129, BASB130 and BASB131 polypeptide, can be introduced or upregulated (e.g. by altering the promoter).

Instead or in addition, the expression of outer-membrane molecules which are either not relevant (e.g. unprotective antigens or immunodominant but variable proteins) or detrimental (e.g. toxic molecules such as LPS, or potential inducers of an autoimmune response) can be downregulated. These approaches are discussed in more detail below.

The non-coding flanking regions of the BASB129, BASB130 and BASB131 gene contain regulatory elements important in the expression of the gene. This regulation takes place both at the transcriptional and translational level. The sequence of these regions, either upstream or downstream of the open reading frame of the gene, can be obtained by DNA sequencing. This sequence information allows the determination of potential regulatory motifs such as the different promoter elements, terminator sequences, inducible sequence elements, repressors, elements responsible for phase variation, the shine-dalgarno sequence, regions with potential secondary structure involved in regulation, as well as other types of regulatory motifs or sequences. This sequence is a further aspect of the invention.

This sequence information allows the modulation of the natural expression of the BASB129, BASB130 and BASB131 gene. The upregulation of the gene expression may be accomplished by altering the promoter, the shine-dalgarno sequence, potential repressor or operator elements, or any other elements involved. Likewise, downregulation of expression can be achieved by similar types of modification. Alternatively, by changing phase variation sequences, the expression of the gene can be put under phase variation control, or it may be uncoupled from this regulation. In another approach, the expression of the gene can be put under the control of one or more inducible elements allowing regulated expression. Examples of such regulation include, but are not limited to, induction by temperature shift, addition of inductor substrates like selected carbohydrates or their derivatives, trace elements, vitamins, co-factors, metal ions, etc.

Such modifications as described above can be introduced by several different means. The modification of sequences involved in gene expression can be carried out *in vivo* by random mutagenesis followed by selection for the desired phenotype. Another approach consists in isolating the region of interest and modifying it by random mutagenesis, or site-directed replacement, insertion or deletion mutagenesis. The modified region can then be reintroduced into the bacterial genome by homologous recombination, and the effect on gene expression can be assessed. In another approach, the sequence knowledge of the region of interest can be used to replace or delete all or part of the natural regulatory sequences. In this case, the regulatory region targeted is isolated and modified so as to contain the regulatory elements from another gene, a combination of regulatory elements from different genes, a synthetic regulatory region, or any other regulatory region, or to delete selected parts of the wild-type regulatory sequences. These modified sequences can then be reintroduced into the bacterium via homologous recombination into the genome. A non-exhaustive list of preferred promoters that could be used for up-regulation of gene expression includes the promoters *porA*, *porB*, *lbpB*, *tbpB*, *p110*, *lst*, *hpuAB* from *N. meningitidis* or *N. gonorrhoeae*; *ompCD*, *copB*, *lbpB*, *ompE*, *UspA1*; *UspA2*; *TbpB* from *M. Catarrhalis*; *p1*, *p2*, *p4*, *p5*, *p6*, *lpD*, *tbpB*, *D15*, *Hia*, *Hmw1*, *Hmw2* from *H. influenzae*.

In one example, the expression of the gene can be modulated by exchanging its promoter with a stronger promoter (through isolating the upstream sequence of the gene, *in vitro* modification of this sequence, and reintroduction into the genome by homologous recombination). Upregulated expression can be obtained in both the bacterium as well as in the outer membrane vesicles shed (or made) from the bacterium.

In other examples, the described approaches can be used to generate recombinant bacterial strains with improved characteristics for vaccine applications. These can be, but are not limited to, attenuated strains, strains with increased expression of selected antigens, strains with knock-outs (or decreased expression) of genes interfering with the immune

response, strains with modulated expression of immunodominant proteins, strains with modulated shedding of outer-membrane vesicles.

Thus, also provided by the invention is a modified upstream region of the BASB129, BASB130 and BASB131 gene, which modified upstream region contains a heterologous regulatory element which alters the expression level of the BASB129, BASB130 and BASB131 protein located at the outer membrane. The upstream region according to this aspect of the invention includes the sequence upstream of the BASB129, BASB130 and BASB131 gene. The upstream region starts immediately upstream of the BASB129, BASB130 and BASB131 gene and continues usually to a position no more than about 1000 bp upstream of the gene from the ATG start codon. In the case of a gene located in a polycistronic sequence (operon) the upstream region can start immediately preceding the gene of interest, or preceding the first gene in the operon. Preferably, a modified upstream region according to this aspect of the invention contains a heterologous promotor at a position between 500 and 700 bp upstream of the ATG.

Thus, the invention provides a BASB129, BASB130 and BASB131 polypeptide, in a modified bacterial bleb. The invention further provides modified host cells capable of producing the non-live membrane-based bleb vectors. The invention further provides nucleic acid vectors comprising the BASB129, BASB130 and BASB131 gene having a modified upstream region containing a heterologous regulatory element.

Further provided by the invention are processes to prepare the host cells and bacterial blebs according to the invention.

Also provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides and/or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. *et al.* Science 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof, which have been shown to encode non-variable regions of bacterial cell surface proteins, in polynucleotide constructs used in such genetic immunization experiments in animal models of infection with *Moraxella catarrhalis*. Such experiments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value, derived from the requisite organ of the animal successfully resisting or clearing infection, for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly *Moraxella catarrhalis* infection, in mammals, particularly humans.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant polypeptide and/or polynucleotide of the invention together with a suitable carrier, such as a pharmaceutically acceptable carrier. Since the polypeptides and polynucleotides may be broken down in the stomach, each is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostatic compounds and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

The vaccine formulation of the invention may also include adjuvant systems for enhancing the immunogenicity of the formulation. Preferably the adjuvant system raises preferentially a TH1 type of response.

An immune response may be broadly distinguished into two extreme categories, being a humoral or cell mediated immune responses (traditionally characterised by antibody and cellular effector mechanisms of protection respectively). These categories of response have been termed TH1-type responses (cell-mediated response), and TH2-type immune responses (humoral response).

Extreme TH1-type immune responses may be characterised by the generation of antigen specific, haplotype restricted cytotoxic T lymphocytes, and natural killer cell responses. In mice TH1-type responses are often characterised by the generation of antibodies of the IgG2a subtype, whilst in the human these correspond to IgG1 type antibodies. TH2-type immune responses are characterised by the generation of a broad range of immunoglobulin isotypes including in mice IgG1, IgA, and IgM.

It can be considered that the driving force behind the development of these two types of immune responses are cytokines. High levels of TH1-type cytokines tend to favour the induction of cell mediated immune responses to the given antigen, whilst high levels of TH2-type cytokines tend to favour the induction of humoral immune responses to the antigen.

The distinction of TH1 and TH2-type immune responses is not absolute. In reality an individual will support an immune response which is described as being predominantly TH1 or predominantly TH2. However, it is often convenient to consider the families of cytokines in terms of that described in murine CD4 +ve T cell clones by Mosmann and Coffman (*Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p145-173*). Traditionally, TH1-type responses are associated with the production of the INF- γ and IL-2 cytokines by T-lymphocytes. Other cytokines often directly associated with the induction of TH1-type immune responses are not

produced by T-cells, such as IL-12. In contrast, TH2- type responses are associated with the secretion of IL-4, IL-5, IL-6 and IL-13.

It is known that certain vaccine adjuvants are particularly suited to the stimulation of either TH1 or TH2 - type cytokine responses. Traditionally the best indicators of the TH1:TH2 balance of the immune response after a vaccination or infection includes direct measurement of the production of TH1 or TH2 cytokines by T lymphocytes *in vitro* after restimulation with antigen, and/or the measurement of the IgG1:IgG2a ratio of antigen specific antibody responses.

Thus, a TH1-type adjuvant is one which preferentially stimulates isolated T-cell populations to produce high levels of TH1-type cytokines when re-stimulated with antigen *in vitro*, and promotes development of both CD8+ cytotoxic T lymphocytes and antigen specific immunoglobulin responses associated with TH1-type isotype.

Adjuvants which are capable of preferential stimulation of the TH1 cell response are described in International Patent Application No. WO 94/00153 and WO 95/17209.

3 De-O-acylated monophosphoryl lipid A (3D-MPL) is one such adjuvant. This is known from GB 2220211 (Ribi). Chemically it is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains and is manufactured by Ribi Immunochem, Montana. A preferred form of 3 De-O-acylated monophosphoryl lipid A is disclosed in European Patent 0 689 454 B1 (SmithKline Beecham Biologicals SA).

Preferably, the particles of 3D-MPL are small enough to be sterile filtered through a 0.22micron membrane (European Patent number 0 689 454).

3D-MPL will be present in the range of 10µg - 100µg preferably 25-50µg per dose wherein the antigen will typically be present in a range 2-50µg per dose.

Another preferred adjuvant comprises QS21, an Hplc purified non-toxic fraction derived from the bark of *Quillaja Saponaria* Molina. Optionally this may be admixed with 3 De-O-acylated monophosphoryl lipid A (3D-MPL), optionally together with an carrier.

The method of production of QS21 is disclosed in US patent No. 5,057,540.

Non-reactogenic adjuvant formulations containing QS21 have been described previously (WO 96/33739). Such formulations comprising QS21 and cholesterol have been shown to be successful TH1 stimulating adjuvants when formulated together with an antigen.

Further adjuvants which are preferential stimulators of TH1 cell response include immunomodulatory oligonucleotides, for example unmethylated CpG sequences as disclosed in WO 96/02555.

Combinations of different TH1 stimulating adjuvants, such as those mentioned hereinabove, are also contemplated as providing an adjuvant which is a preferential stimulator of TH1 cell response. For example, QS21 can be formulated together with 3D-MPL. The ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; preferably 1:5 to 5 : 1 and often substantially 1 : 1. The preferred range for optimal synergy is 2.5 : 1 to 1 : 1 3D-MPL: QS21.

Preferably a carrier is also present in the vaccine composition according to the invention. The carrier may be an oil in water emulsion, or an aluminium salt, such as aluminium phosphate or aluminium hydroxide.

A preferred oil-in-water emulsion comprises a metabolisable oil, such as squalene, alpha tocopherol and Tween 80. In a particularly preferred aspect the antigens in the vaccine composition according to the invention are combined with QS21 and 3D-MPL in such

an emulsion. Additionally the oil in water emulsion may contain span 85 and/or lecithin and/or tricaprylin.

Typically for human administration QS21 and 3D-MPL will be present in a vaccine in the range of 1 μ g - 200 μ g, such as 10-100 μ g, preferably 10 μ g - 50 μ g per dose.

Typically the oil in water will comprise from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80. Preferably the ratio of squalene: alpha tocopherol is equal to or less than 1 as this provides a more stable emulsion. Span 85 may also be present at a level of 1%. In some cases it may be advantageous that the vaccines of the present invention will further contain a stabiliser.

Non-toxic oil in water emulsions preferably contain a non-toxic oil, e.g. squalane or squalene, an emulsifier, e.g. Tween 80, in an aqueous carrier. The aqueous carrier may be, for example, phosphate buffered saline.

A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210.

The present invention also provides a polyvalent vaccine composition comprising a vaccine formulation of the invention in combination with other antigens, in particular antigens useful for treating cancers, autoimmune diseases and related conditions. Such a polyvalent vaccine composition may include a TH-1 inducing adjuvant as hereinbefore described.

While the invention has been described with reference to certain BASB129, BASB130 and BASB131 polypeptides and polynucleotides, it is to be understood that this covers fragments of the naturally occurring polypeptides and polynucleotides, and similar polypeptides and polynucleotides with additions, deletions or substitutions which do not

substantially affect the immunogenic properties of the recombinant polypeptides or polynucleotides.

Compositions, kits and administration

In a further aspect of the invention there are provided compositions comprising a BASB129, BASB130 and BASB131 polynucleotide and/or a BASB129, BASB130 and BASB131 polypeptide for administration to a cell or to a multicellular organism.

The invention also relates to compositions comprising a polynucleotide and/or a polypeptides discussed herein or their agonists or antagonists. The polypeptides and polynucleotides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to an individual. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide and/or polynucleotide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide and/or polynucleotide, such as the soluble form of a polypeptide and/or polynucleotide of the present invention, agonist or antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, solutions, powders and the like.

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular

individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 $\mu\text{g/kg}$ of subject.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Sequence Databases, Sequences in a Tangible Medium, and Algorithms

Polynucleotide and polypeptide sequences form a valuable information resource with which to determine their 2- and 3-dimensional structures as well as to identify further sequences of similar homology. These approaches are most easily facilitated by storing the sequence in a computer readable medium and then using the stored data in a known macromolecular

structure program or to search a sequence database using well known searching tools, such as the GCG program package.

Also provided by the invention are methods for the analysis of character sequences or strings, particularly genetic sequences or encoded protein sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, DNA, RNA and protein structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, codon usage analysis, nucleic acid base trimming, and sequencing chromatogram peak analysis.

A computer based method is provided for performing homology identification. This method comprises the steps of: providing a first polynucleotide sequence comprising the sequence of a polynucleotide of the invention in a computer readable medium; and comparing said first polynucleotide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

A computer based method is also provided for performing homology identification, said method comprising the steps of: providing a first polypeptide sequence comprising the sequence of a polypeptide of the invention in a computer readable medium; and comparing said first polypeptide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

DEFINITIONS

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heine, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GAP program in the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN (Altschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990), and FASTA(Pearson and Lipman *Proc. Natl. Acad. Sci. USA* 85: 2444-2448 (1988). The BLAST family of programs is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Parameters for polypeptide sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

Comparison matrix: BLOSSUM62 from Henikoff and Henikoff,
Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992)

Gap Penalty: 8

Gap Length Penalty: 2

A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Parameters for polynucleotide comparison include the following:

Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below.

(1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to the reference sequence of SEQ ID NO:1, wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO:1 or may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more

contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in SEQ ID NO:1, y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and \bullet is the symbol for the multiplication operator, and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is it may be 100% identical, or it may include up to a certain integer number of nucleic acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleic acids in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein n_n is the number of nucleic acid alterations, x_n is the total number of nucleic acids in SEQ ID NO:1, y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., \bullet is the symbol for the multiplication operator, and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n .

(2) Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 50,60, 70, 80, 85, 90, 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may be identical to the reference sequence of SEQ ID NO:2 or may include up to a certain integer number of amino acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2, y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and \bullet is the symbol for

the multiplication operator, and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

By way of example, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is it may be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2, y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and \bullet is the symbol for the multiplication operator, and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

"Individual(s)," when used herein with reference to an organism, means a multicellular eukaryote, including, but not limited to a metazoan, a mammal, an ovid, a bovid, a simian, a primate, and a human.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA including single and double-stranded regions.

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring

variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Disease(s)" means any disease caused by or related to infection by a bacteria, including, for example, otitis media in infants and children, pneumonia in elderlies, sinusitis, nosocomial infections and invasive diseases, chronic otitis media with hearing loss, fluid accumulation in the middle ear, auditive nerve damage, delayed speech learning, infection of the upper respiratory tract and inflammation of the middle ear.

EXAMPLES:

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.

Example 1: DNA sequencing of the BASB129, BASB130 and BASB131 gene from *Moraxella catarrhalis* strain ATCC 43617.

The BASB129, BASB130 and BASB131 gene of SEQ ID NO:1, 3 or 5 is from *Moraxella catarrhalis* strain ATCC 43617. The translation of the BASB129, BASB130 and BASB131 polynucleotide sequence is showed in SEQ ID NO:2, 4 or 6.

Example 2: Construction of Plasmid to Express Recombinant BASB129, BASB130 AND BASB131

A: Cloning of BASB129, BASB130 AND BASB131 .

The *Eco*RI and *Sa*I restriction sites engineered into reverse amplification primers, permit directional cloning of a PCR product into the *E.coli* expression plasmid pTLZ2 such that a mature BASB129, BASB130 or BASB131 protein can be expressed as a fusion protein containing a (His)₆ affinity chromatography tag at the C-terminus. The BASB129, BASB130 and BASB131 PCR product is purified from the amplification reaction using silica gel-based spin columns (QiaGen) according to the manufacturers instructions. To produce the required *Eco*RI and *Sa*I termini necessary for cloning, purified PCR product is sequentially digested to completion with *Eco*RI and *Sa*I restriction enzymes as recommended by the manufacturer (Life Technologies). Following the first restriction digestion, the PCR product is purified via spin column as above to remove salts and eluted in sterile water prior to the second enzyme digestion.

The digested DNA fragment is again purified using silica gel-based spin columns prior to ligation with the pTLZ2 plasmid.

B: Production of Expression Vector.

To prepare the expression plasmid pTLZ2 for ligation, it is similarly digested to completion with both *EcoRI* and *SaII* and then treated with calf intestinal phosphatase (CIP, ~0.02 units / pmole of 5' end, Life Technologies) as directed by the manufacturer to prevent self ligation. An approximately 5-fold molar excess of the digested fragment to the prepared vector is used to program the ligation reaction. A standard ~20 μ l ligation reaction (~16°C, ~16 hours), using methods well known in the art, is performed using T4 DNA ligase (~2.0 units / reaction, Life Technologies). An aliquot of the ligation (~5 μ l) is used to transform electro-competent JM109 cells according to methods well known in the art. Following a ~2-3 hour outgrowth period at 37°C in ~1.0 ml of LB broth, transformed cells are plated on LB agar plates containing ampicillin (100 μ g/ml). Antibiotic is included in the selection. Plates are incubated overnight at 37°C for ~16 hours. Individual ApR colonies are picked with sterile toothpicks and used to "patch" inoculate fresh LB ApR plates as well as a ~1.0 ml LB ApR broth culture. Both the patch plates and the broth culture are incubated overnight at 37°C in either a standard incubator (plates) or a shaking water bath. A whole cell-based PCR analysis is employed to verify that transformants contain the BASB129, BASB130 and BASB131 DNA insert. Here, the ~1.0 ml overnight LB Ap broth culture is transferred to a 1.5 ml polypropylene tube and the cells collected by centrifugation in a Beckmann microcentrifuge (~3 min., room temperature, ~12,000 X g). The cell pellet is suspended in ~200 μ l of sterile water and a ~10 μ l aliquot used to program a ~50 μ l final volume PCR reaction containing both BASB129, BASB130 and BASB131 forward and reverse amplification primers. Final concentrations of the PCR reaction components are essentially the same as those specified in example 2 except ~5.0 units of *Taq* polymerase is used. The initial 95°C denaturation step is increased to 3 minutes to ensure thermal disruption of the bacterial cells and liberation of plasmid

DNA. An ABI Model 9700 thermal cycler and a 32 cycle, three-step thermal amplification profile, i.e. 95°C, 45sec; 55-58°C, 45sec, 72°C, 1min., are used to amplify the BASB129, BASB130 AND BASB131 fragment from the lysed transformant samples. Following thermal amplification, a ~20µl aliquot of the reaction is analyzed by agarose gel electrophoresis (0.8 % agarose in a Tris-acetate-EDTA (TAE) buffer). DNA fragments are visualized by UV illumination after gel electrophoresis and ethidium bromide staining. A DNA molecular size standard (1 Kb ladder, Life Technologies) is electrophoresed in parallel with the test samples and is used to estimate the size of the PCR products. Transformants that produced the expected size PCR product are identified as strains containing a BASB129, BASB130 and BASB131 expression construct. Expression plasmid containing strains are then analyzed for the inducible expression of recombinant BASB129, BASB130 and BASB131 .

C: Expression Analysis of PCR-Positive Transformants.

For each PCR-positive transformant identified above, ~5.0 ml of LB broth containing ampicillin (100 µg/ml) is inoculated with cells from the patch plate and grown overnight at 37 °C with shaking (~250 rpm). An aliquot of the overnight seed culture (~1.0 ml) is inoculated into a 125 ml erlenmeyer flask containing ~25 of LB Ap broth and grown at 37 °C with shaking (~250 rpm) until the culture turbidity reaches O.D.600 of ~0.5, i.e. mid-log phase (usually about 1.5 - 2.0 hours). At this time approximately half of the culture (~12.5 ml) is transferred to a second 125 ml flask and expression of recombinant BASB129, BASB130 and BASB131 protein induced by the addition of IPTG (1.0 M stock prepared in sterile water, Sigma) to a final concentration of 1.0 mM. Incubation of both the IPTG-induced and non-induced cultures continues for an additional ~4 hours at 37 °C with shaking. Samples (~1.0 ml) of both induced and non-induced cultures are removed after the induction period and the cells collected by centrifugation in a microcentrifuge at room temperature for ~3 minutes. Individual cell pellets are suspended in ~50µl of sterile water, then mixed with an equal volume of 2X Laemelli SDS-PAGE sample buffer containing 2-mercaptoethanol, and placed in

boiling water bath for ~3 min to denature protein. Equal volumes (~15µl) of both the crude IPTG-induced and the non-induced cell lysates are loaded onto duplicate 12% Tris/glycine polyacrylamide gel (1 mm thick Mini-gels, Novex). The induced and non-induced lysate samples are electrophoresed together with prestained molecular weight markers (SeeBlue, Novex) under conventional conditions using a standard SDS/Tris/glycine running buffer (BioRad). Following electrophoresis, one gel is stained with commassie brilliant blue R250 (BioRad) and then destained to visualize novel BASB129, BASB130 and BASB131 IPTG-inducible protein(s). The second gel is electroblotted onto a PVDF membrane (0.45 micron pore size, Novex) for ~2 hrs at 4 °C using a BioRad Mini-Protean II blotting apparatus and Towbin's methanol (20 %) transfer buffer. Blocking of the membrane and antibody incubations are performed according to methods well known in the art. A monoclonal anti-RGS (His)₃ antibody, followed by a second rabbit anti-mouse antibody conjugated to HRP (QiaGen), is used to confirm the expression and identity of the BASB129, BASB130 and BASB131 recombinant protein. Visualization of the anti-His antibody reactive pattern is achieved using either an ABT insoluble substrate or using Hyperfilm with the Amersham ECL chemiluminescence system.

Example 3: Production of Recombinant BASB129, BASB130 AND BASB131

Bacterial strain

A recombinant expression strain of *E. coli* JM109 containing a plasmid (pTLZ2) encoding BASB129, BASB130 or BASB131 from *M. catarrhalis*. is used to produce cell mass for purification of recombinant protein. The expression strain is cultivated on LB agar plates containing 100µg/ml ampicillin ("Ap") to ensure that the pTLZ2 was maintained. For cryopreservation at -80 °C, the strain is propagated in LB broth containing the same concentration of antibiotics then mixed with an equal volume of LB broth containing 30% (w/v) glycerol.

Media

The fermentation medium used for the production of recombinant protein consists of 2X YT broth (Difco) containing 100µg/ml Ap. Antifoam is added to medium for the fermentor at 0.25 ml/L (Antifoam 204, Sigma). To induce expression of the BASB129, BASB130 or BASB131 recombinant protein, IPTG (Isopropyl β-D-Thiogalactopyranoside) is added to the fermentor (1 mM, final).

Fermentation

A 500-ml erlenmeyer seed flask, containing 50ml working volume, is inoculated with 0.3 ml of rapidly thawed frozen culture, or several colonies from a selective agar plate culture, and incubated for approximately 12 hours at $37 \pm 1^\circ\text{C}$ on a shaking platform at 150rpm (Innova 2100, New Brunswick Scientific). This seed culture is then used to inoculate a 5-L working volume fermentor containing 2X YT broth and both Ap antibiotics. The fermentor (Bioflo 3000, New Brunswick Scientific) is operated at $37 \pm 1^\circ\text{C}$, 0.2 - 0.4 VVM air sparge, 250 rpm in Rushton impellers. The pH is not controlled in either the flask seed culture or the fermentor. During fermentation, the pH range is 6.5 to 7.3 in the fermentor. IPTG (1.0 M stock, prepared in sterile water) is added to the fermentor when the culture reaches mid-log of growth (~ 0.7 O.D.600 units). Cells are induced for 2 - 4 hours then harvested by centrifugation using either a 28RS Heraeus (Sepatech) or RC5C superspeed centrifuge (Sorvall Instruments). Cell paste is stored at -20 C until processed.

Example 4: Purification of recombinant BASB129, BASB130 AND BASB131 from *E. coli*

Extraction-Purification

Cell paste from IPTG induced culture is resuspended in 60 ml of phosphate buffer pH 7.5 containing 1mM AEBSF and 1mM Aprotinin as protease inhibitors. Cells are lysed in a cell disruptor, centrifuged, washed and re-centrifuged. The pellet is suspended in 100 mM NaH_2PO_4 , 10 mM Tris-HCl buffer pH 8 containing 6M Guanidium Chloride (buffer A) and left for 1 h ur at room temperature. Total extract is centrifuged at

27,000g for 20 minutes. Supernatant is incubated for 1 hour at room temperature with Ni-NTA superflow resin equilibrated in buffer A. Resin is washed twice with 100 mM NaH_2PO_4 , 10 mM Tris-HCl buffer pH 6.3, containing 8M Urea (buffer B). Elution is performed successively with buffer B adjusted to pH 5.9 then pH 4.5. Fractions containing BASB121 antigen are neutralized with 25% volume of 0.2M phosphate buffer pH 7.5. Pooled fractions are dialysed successively against 100 mM NaH_2PO_4 containing 8M Urea, then 4M Urea, then 2M Urea and finally against PBS pH 7.4 containing 0.1% Triton X-100.

Purified BASB129, BASB130 and BASB131 antigen is quantified using Micro BCA assay reagent.

Example 5: Production of Antisera to Recombinant BASB129, BASB130 AND BASB131

Polyvalent antisera directed against the BASB129, BASB130 and BASB131 protein are generated by vaccinating rabbits with the purified recombinant BASB129, BASB130 and BASB131 protein. Animals are bled prior to the first immunization ("pre-bleed") and after the last immunization.

Anti-BASB129, BASB130 and BASB131 protein titres are measured by an ELISA using purified recombinant BASB129, BASB130 and BASB131 protein. The titre is defined as mid-point titers calculated by 4-parameter logistic model using the XL Fit software.

The antisera are also used as the first antibody to identify the protein in a western blot as described in example 7 below. The western-blot is used to demonstrate the presence of anti-BASB129, BASB130 and BASB131 antibody in the sera of immunized animals.

Example 6: Immunological characterization: Surface exposure of BASB129,

BASB130 AND BASB131

Anti-BASB129, BASB130 AND BASB131 protein titres are determined by an ELISA using formalin-killed whole cells of *Moraxella catarrhalis*. The titre is defined as mid-point titers calculated by 4-parameter logistic model using the XL Fit software.

The titre observed with the rabbit or mouse immune sera demonstrates that the BASB129, BASB130 AND BASB131 protein is present at the surface of *M. catarrhalis* cells.

Example 7. Immunological Characterisation: Western Blot Analysis

Several strains of *M. catarrhalis* including ATCC 43617, as well as clinical isolates from various geographic regions, are grown on Muller Hinton agar plates for 24 hours at 36°C. Several colonies are used to inoculate broth. Cultures are grown until the A620 is approximately 0.6 and cells are collected by centrifugation. Cells are then concentrated and solubilized in PAGE sample buffer. The solubilized cells are then resolved on 4-20% polyacrylamide gels and the separated proteins are electrophoretically transferred to PVDF membranes. The PVDF membranes are then pretreated with saturation buffer. All subsequent incubations are carried out using this pretreatment buffer.

PVDF membranes are incubated with preimmune serum or rabbit or mouse immune seru. PVDF membranes are then washed.

PVDF membranes are incubated with biotin-labeled sheep anti-rabbit or mouse Ig. PVDF membranes are then washed 3 times with wash buffer, and incubated with streptavidin-peroxydase. PVDF membranes are then washed 3 times with wash buffer and developed with 4-chloro-1-naphtol.

Detection of a protein corresponding to BASB129, BASB130 and BASB131 expected molecular weight that is reactive with the antisera is used to demonstrate that this protein is produced by and conserved in all *Moraxella* strains tested.

Example 8: Immunological characterization: Bactericidal Activity

Complement-mediated cytotoxic activity of anti-BASB129, BASB130 and BASB131 antibodies is examined to determine the vaccine potential of BASB129, BASB130 and BASB131 protein antiserum that is prepared as described above. The activities of the pre-immune serum and the anti-BASB129, BASB130 and BASB131 antiserum in mediating complement killing of *M. catarrhalis* are examined.

Strains of *M. catarrhalis* are grown on plates. Several colonies are added to liquid medium. Cultures are grown and collected until the A620 is approximately 0.4. After one wash step, the pellet is suspended and diluted.

Preimmune sera and the anti-BASB129, BASB130 and BASB131 sera is deposited into the first well of a 96-wells plate and serial dilutions are deposited in the other wells of the same line. Live diluted *M. catarrhalis* is subsequently added and the mixture is incubated. Complement is added into each well at a working dilution defined beforehand in a toxicity assay.

Each test includes a complement control (wells without serum containing active or inactivated complement source), a positive control (wells containing serum with a know titer of bactericidal antibodies), a culture control (wells without serum and complement) and a serum control (wells without complement).

Bactericidal activity of rabbit or mice antiserum (50% killing of homologous strain) is measured.

Example 9: Presence of Antibody to BASB129, BASB130 AND BASB131 in Human Convalescent Sera

Western blot analysis of purified recombinant BASB129, BASB130 and BASB131 is performed as described in Example 7 above, except that a pool of human sera from children infected by *M. catarrhalis* is used as the first antibody preparation. This is used to show that antisera from naturally infected individuals react to the purified recombinant protein.

**Example 10: Efficacy of BASB129, BASB130 AND BASB131 vaccine:
enhancement of lung clearance of *M. catarrhalis* in mice.**

This mouse model is based on the analysis of the lung invasion by *M. catarrhalis* following a standard intranasal challenge to vaccinated mice.

Groups of mice are immunized with BASB129, BASB130 and BASB131 vaccine. After the booster, the mice are challenged by instillation of bacterial suspension into the nostril under anaesthesia. Mice are killed between 30 minutes and 24 hours after challenge and the lungs are removed aseptically and homogenized individually. The log₁₀ weighted mean number of CFU/lung is determined by counting the colonies grown on agar plates after plating of dilutions of the homogenate. The arithmetic mean of the log₁₀ weighted mean number of CFU/lung and the standard deviations are calculated for each group.

Results are analysed statistically.

In this experiment groups of mice are immunized either with BASB129, BASB130 and BASB131 or with a killed whole cells (kwc) preparation of *M. catarrhalis* or sham immunized.

This is used to show that the kwc preparation and the BASB129, BASB130 and BASB131 vaccine induce significant lung clearance as compared to the control group.

Example 11: Inhibition of *M. catarrhalis* adhesion nt cells by anti-BASB129, BASB130 AND BASB131 antiserum.

This assay measures the capacity of anti BASB129, BASB130 AND BASB131 sera to inhibit the adhesion of *Moraxella* bacteria to epithelial cells. This activity could prevent colonization of f.i. the nasopharynx by *Moraxella*.

One volume of bacteria is incubated on ice with one volume of pre-immune or anti-BASB129, BASB130 and BASB131 immune serum dilution. This mixture is subsequently added in the wells of a 24 well plate containing a confluent cells culture that is washed once with culture medium to remove traces of antibiotic. The plate is centrifuged and incubated.

Each well is then gently washed. After the last wash, sodium glycocholate is added to the wells. After incubation, the cell layer is scraped and homogenised. Dilutions of the homogenate are plated on agar plates and incubated. The number of colonies on each plate is counted and the number of bacteria present in each well calculated.

This is used to show that bacteria incubated with anti-BASB129, BASB130 and BASB131 antiserum are inhibited in their adherence capacity to the Hep-2 cells.

Deposited materials

A deposit containing a *Moraxella catarrhalis* Catlin strain has been deposited with the American Type Culture Collection (herein "ATCC") on June 21, 1997 and assigned deposit number 43617. The deposit was described as *Branhamella catarrhalis* (Frosch and Kolle) and is a freeze-dried, 1.5-2.9 kb insert library constructed from *M. catarrhalis* isolate obtained from a transtracheal aspirate of a coal miner with chronic bronchitis. The deposit is described in Antimicrob. Agents Chemother. 21: 506-508 (1982).

The *Moraxella catarrhalis* strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."

The deposited strain contains a full length BASB129, BASB130 and BASB131 gene.

A deposit of the vector pMC-D15 consisting of *Moraxella catarrhalis* DNA inserted in pQE30 has been deposited with the American Type Culture Collection (ATCC) on February 12 1999 and assigned deposit number 207105.

The sequence of the polynucleotides contained in the deposited strain / clone, as well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.

The deposit of the deposited strains have been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The deposited strains will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strains are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

Applicant's or agent's file FB/BM45414 reference number	International application No. PCT/EP 00 / 09034
--	---

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 65 lines 1-28.	
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet <input type="checkbox"/>
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 10801 UNIVERSITY BLVD, MANASSAS, VIRGINIA 20110-2209, UNITED STATES OF AMERICA	
Date of deposit 21 June 1997 and 12 February 1999	Accession Number 43617 and 207105
C. ADDITIONAL INDICATIONS (leave blank if not applicable)	This information is continued on an additional sheet <input type="checkbox"/>
In respect of those designations where a European Patent is sought, a sample of the deposited microorganisms will be made available until the publication of the mention of the grant of the European Patent or until the date on which the application has been refused or withdrawn, only by issue of such a sample to an expert nominated by the person requesting the sample.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input type="checkbox"/>	This sheet was received with the international application
Authorized officer	

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau on:
Authorized officer	

SEQUENCE INFORMATION

BASB129, BASB130 and BASB131 P lynnucleotide and P lypeptide Sequences

SEQ ID NO:1

Moraxella catarrhalis BASB129 polynucleotide sequence from strain ATCC43617

ATGAAAGCACAAATTTACAACCCATAAAGTCATCGGCGGACTATTTGTAGGTGGCATGATGCTAAATGCACATGCAGCACC
TGAATTATATGGTTACGCAATCTTGTCTGCTAATCATAAAAAACAACCAACAAGACAACCAATGTCAGTACAT
CAACAACAGACCGCCCTATCTGTATAGCAGCGGATCACGCATTGGCCTTAGAGGGTCTGAAAAGTTAAATGATGATTAT
GAGGTTTTGTACAAGTTGGAGTACCGTCTAGAAAATGATGGTGATTACGCAATGAAAAATCAAGCAGCCAGATGGTAC
TGAAAAGACTGTTGCTAAAACACGCAATTTTGAGGCTCGTGATTTCATGGATTGGCGTGAAGCATAAAAAGTATGGTACCA
TCAAGGCGGGTCGTATGTTGTCTTTGGATCCATATGTGCGTTATACTGCCTATTTGGCGTCAGGCGTAGATGGGGTGCCT
ACCAATAATACCATTGCATACGAATCACCAAAATCAAAGATGTTAGTTTTCAGGCGATGTACATCTTAGATGAAAATAA
AGAGACAGATACCATTGATCGTGATGGTTATTCATTGCTTGTCAAGAAAAACACAGATACATATAATGTTGGTGCAGCTT
ATGCCATTTTTGGTAAAGCAAAAACCTCTTATGGCAAGATTAATACTACTGCGCGTGTGACAGGTAATTATAAAATTAAT
GAGGATTATAAAGTAGGTGGTATCTATCAGCATGTGCGCTATGCCAATGACGACAGTGCCAAAAATAATACAGAACAAAGC
TGTTGGCGTGGCTTTGCAGCATTTTAAAGACAAATGGACTCATACCGCACACATGAATCTTGTGAATAATCCTAGTGGGA
AAAAGGGCGATGGGTTTGTAGCTGATCGGAGCAATTGACCGTGATATTTCTAAAAATGTCTCTGCAGGCATGGATATCACC
TATGGTAACTTTAACTACGCAACAGAAAAAGAATCTTACATCAACCAACTATCTATGCGACTGTATATTTTTAA

SEQ ID NO:2

Moraxella catarrhalis BASB129 polypeptide sequence deduced from the polynucleotide of SEQ ID NO:1

MKAQFTTLKVIIGLFGVGMMLNAHAPELYGYANLVVSANHKRTTNKNTNVSTSTTDRPYLYSSGSRIGLRGSEKLNDDYE
VLYKLEYRLNDGDLRNEKIKQPDGTEKTVAKTRNFEARDSWIGVKHKYGTIKAGRMLSLDPYVRYTAYLASGVDGVRTN
NTIAYESPRIKIDVSFQAMYILDENKETDTIDRDGYSLLVKKNTDTYNVGAAYAYFGKAKTSYGKINYTARVTGNKYKINEDY
KVGGIYQHVGYANDDSAKNTEQAVGVVALQHFKDKWHTAHMNLVNNPSSGKKGDGFELIGAIDRDISKNVSAGMDITYGNF
NYATEKESYINPTIYATVYF

SEQ ID NO:3

Moraxella catarrhalis BASB130 polynucleotide sequence from strain ATCC43617

ATGCGTTTTATACCTTTTGTGTAACCTTTTATCTTTTACTGGCTCCTCCATCTTTTCTGTGGCCAAAGCTCAGATTGC
ACCAGACCCAACCAAAGCAAATCTTTCTGCAATAACCGATGATCGTCGTGAGGCGGCTCTTGACATTTAGCAAGACAAG
ATTTGGCAGCAACAGATGACGACATGGGTGTCGATATCAATCAAACCAATATCAACCAGCCAAATTTGGCAAGATGACAAG
AATGGCGATTTCATGTTTTTGGTTGATGAGATTGACTTTGTGATTGAGGGTGGAGAAGATAAACATATTCTAGGTATGAC
GCCGAGCAATTTACGCGCTTGCTATCGCCCTGTTGGACCGGACAAAGCCAAACATATGCTCTTAATCACTGCATCAACA
ATCACAACCTATCTTTAATTGTAGATATTGCCATAATGAATTACTAAAGCGTGGTTATTTAACTAGCAGTATTAGCATT
GAAGAGCAGGATTATCAACTAAAAAATCACTTTAACAGTCCATGCTGGCAAGGTGAAAAAGGTGATATTGGCCGATGC
TAGCAAAACGCCAACTTATGTCAAAGCCGCCATTCTCTTAAAGTTCAATCAAGCCTTTTCGTCTGTATATTAGAACAAG
GTCTAGATAATTTAAACGCATCGATCCAACGGCAACCGTGACATTATACCAAGCAGCTCCAGTAATGTCGCCAATGAT
ATTGACATTAAACACCACAAACCTTGGTTTTAGTGATTTACTCATTAGGATGGACCGCAGTCAAAGCGCTGATTTTGGCAT
TAATATTGATAACAGTTTATCCAAAGATTATGGCAATTATCTGATTTCTGCTAATGTTTCGTGCTAAACAACCTCATGCATC
TTAACGATGAATGGAATCTTTCTGCCAACTATCCATTGGCGCGCCTGATTGACGCTGCCAAAAATGATCTTGGGGTTTCAG
GTGGGCAAGGATAGGCAGGTTAATTATCAGCTTCCTTGACTATTCTTATGGATTGTATAAATTTTCTGCCACACACAG
CCACCACCAATACCAGCAATTTCTGAAGGGCTTCATGCGCCCTTGACTTATCATGGCACCAGCAAGACAAGCTCAATTG

GATTGTCTCGTTTATTGCACCGTGATGGCAATCAAAGACTGAAGGTTATATAAAGGTTAATCACAACGAAGCAGTAAT
 TATATTGATGATGTTAATCTTGAAGTGCAAAACCGCCGCACAACAGGATATAACATTGGCATCACTCATCAGCATCATCT
 TCACCAAGGTGGTTATTTGTATGCCAACTTGGATTATAAGCAAGGAACAGGGGCACTAAAAGCAAAGCCTGCACCTGAAG
 AGCATATTTATGATGCTTTTGGGCGACAACCTACCCAGTGAGGGTTTTCGAAAAGCACCAATTTGGTCACTATACACCACT
 TTCCAAAAGCCATTTGTGTTAAACAACCCAAATGATACTGAACAAGCGCAAGATAAAGCAACAGCAAATAAACCCATTTA
 CACATCCATTCTCTCACTTATACTGCTAGATTACAAGCCCAATATGCCAAACAACCTTCTGTACCATCTGATTATTCT
 ATTTGGGTGGCAGATATAGCATTAAAGGCATTAAAGAGGGAAATTATTTATCAGGAGAACATGGCTTTAGCCTATCCCAA
 GAACTTGGCTTGGCAATTGCCATTACAGAATCTTAATCAGCACTTTAGTACAAATGCAACAGCGCCCACTTGTATGCAAG
 TATTGATCAAGGCTATGCCTATGGAAAAACACTCTTAATAATCAACGCCATATCTTGGCTGGAGCGGTTGGTATGAGGT
 ATTATTTCAAGGCAGTCAAGATCCAAGAATTCAAGAAACACAAAATGGCTTGACTCATTTCAAAGAATCAAATACTTAT
 CTAATAACACACCAACCACAGCTCATTGGATATATTCAATTGGAAAAGGAATTAAGACGCCTGAATTTATGAAGAAAGA
 AACCGTCGTGGGTGTGAGTGCCAGCATTGAGTTTAA

SEQ ID NO:4

Moraxella catarrhalis BASB130 polypeptide sequence deduced from the polynucleotide of
 SEQ ID NO:3

MRFI PFAVTLLSFTGSSIFSVARQIAPDPTKANLSAITDDRRQAALAHARQDLAATDDDMGVDINQTNINQPNWQDDKN
 GDSCFLVDEIDFVIEGGEDKHILGMPNLSRLSPLLDRTKPTYALNHCINNHNLSLIVDIAHNELLKRGYLTSSISIEE
 QDLSTKRLTLTVHAGVKVKVILADASKTPTYVKAAPLKFNQAFRLSYLEQGLDNLKRIDPTATVQIIPSSSSNVANDIDI
 NTTNLGFSDLLIRMDRSQSAVFGINIDNSLSKDYGNYLISANVRANMLHLNDEWNLSANYPLARLIDAAQNDLGVQVQKD
 RQVNYHASLTIPYGLYKFSATHSHHQYQQFLEGLHAPLTYHGTSKTSISIGLSRLLHRDGNQRTGEYIKVNHKRSSNYIDDV
 NLEVQNRRTTGYNIGITHQHHLHQGGYLYANLDYKQGTGALKAKPAPEEHIYDAFGRQLPSEGFAPKIWSLYTSFQKPFV
 LNNPNDEQAQDKATANKPIYTSIPLTYTARLQAQYAKQLPVPSDLFYLGGRYSIKGIKEGNYLSGEHGFSLSQELAWQLP
 LQNLNQHFSTNANSAQLYASIDQYAYGKNTLNNQRHILAGAVGMRYYPQGSQDPRIQETQNLTHFKESNTYLNNTPTTA
 HLDIFIGKGIKTPFEMKRETVVGVSASIEF

SEQ ID NO:5

Moraxella catarrhalis BASB131 polynucleotide sequence from strain ATCC43617

ATGAAAATGCCCTATTTTGTCTTTTGGGATTATTGTTAGTACAGCAGGCTGATGCTGATTATAGCTTGCTTGATGCCCA
 AAAACAGCTCATGAGCAGCAGCCCTGCCATCCAAGCAAGTCATGCCTTGATCAAGCTGATGCTTACAAGCAGAATCAT
 TACAAAAATTACACTATCTAGGATATCGCTCAATGCACACGCCCTTTGACTGCAACAAAACAGCAGCATACCCCTTAGAT
 CATATCAAAGAGCAGACCGCCAGCACATTAACACCCATTTTGACCATCGCTTTGGCAGTGCCCCCGATGGTCTGTTGGA
 TGCTTTGCACAAACAGCACCCAAACCGCCCTTGACCGCCTGCCTGACCATCAAGATGTCAAGTTACGCCATGATGGCATT
 CCCCAAACATTACCGCCAGCATACCCATCTATACAGGTGGCTTAATCAGCAGCACCAAAAATATCGCCAATCTACAAGCA
 CAGCGTGGTAAATTTGGATTACAAGAACGCATCTCTTTGGCAAACTTAATTTGATTGCGCATTATTTAATGTGCAATT
 ACAAAGCAGCTGACCGACACACAACAAACATGCTTAGTGCCATGCAGTTACATGTAGATAATGCTTATAAATTAGAAC
 AGCAAGGTTTTATCAGTCGTGGACAGCGTATGCAATTTGAAGTGGCAGCAATCAGGTACAAAGACTGTATCAAAGCACC
 CAAAATCAGCACCAAAAACAGCATTATGAACTTGCTGTTTTGCTTGGTTTGCCCCACATTGAACCGCTAAGCACACCGCT
 GTTTATCAACACCCAGCATCGCCCCAATTGGCAAGCATTACTCAAAGACTCCCAAAATACACCATTAATCAAAGCTAA
 AAACCGACATTTTGCTTGCCGATGAAAATATCGCCCTAAGACAATCCACCAAAAAACCAAAATTGCCGCTGTGGCTCGT
 TATACCTTAGATGATAAGCCTGATTGGTTTGAGGTGTGGCGGTTCTTACAACCTATTCTTGGGCATTGACCGTGATAA
 GCAGATTGGGCGAGCACCTACAAAAACAAGCAGCCCAATTGGGTCATGAACAAGTCAATGAACACATCACAACCACCA
 TGCACACCGCTTATGGCGAGATGGTGTGGCACAAAAAACCCAGCCCTACTACAACAAATCGTCAAGCCGCCAAAGAA
 AATTTGCGTATCCAGACGCTGTCTTTCAAGAAGGTTTGGGACGGTGGCAGGTGTGGTTGATGCCCAAAGTGCTTTATC
 ACAGATTGACAGCGAAACCGCTCTAAATGCGTATCGCTACCTTTTGGCACTGGCGACCGCTGTGCATTACACAGGGACAA
 TTGATGACTTTGATGATTATTTGCTTTGGATGATGCTCATAACTGTGA

SEQ ID NO:6

***Moraxella catarrhalis* BASB131 p lypeptide sequence deduced from the polynucle tide of
SEQ ID NO:5**

MKMPYFLLGLLLVQQADADYSLLDAQQLMSSSPAIQASHALYQADVLQAESLQKLHYPRISLNAHAFVLQONSSIPLDH
IKEQTAQHINTHFDHRFGSAPDGLLDALHNSTQTALDRLPDHQDVKLRRHDGITPNITATIPITYTGGLISSTKNIANLQAQR
GKFGQLQERISLAKLNLIRHYFNVOLQKQLTDTQQNMLSAMQLHVDNAYKLEQQGFISRGORMQFEVARNQVQRLYQSTQNG
HQNSIYELAVLLGLPHIEPLSTPLFINTQHRPNWQALLKDSQNTPLNQKLKTDILLADENIALRQSTKKPKIAAVARYTLD
DKPDWFAGVAVSYNLFGLIDRDKQIGAAHLQKQAAQLGHEQVNEHITTTMHTAYGEMVLAQKTHALLQONRQAAKENLRIQ
TLSFQEGFGTVAGVVDQAQSALSQIDSETALNAYRYLLALATLLHYTGTIDDFDDYLSLDDAHL

CLAIMS:

1. An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6, over the entire length of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6 respectively.
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6, over the entire length of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6 respectively.
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6.
4. An isolated polypeptide of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6.
5. An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic activity of said immunogenic fragment is substantially the same as the polypeptide of SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6.
6. A polypeptide as claimed in any of claims 1 to 5 wherein said polypeptide is part of a larger fusion protein.
7. An isolated polynucleotide encoding a polypeptide as claimed in any of claims 1 to 6.
8. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence of SEQ ID NO:2; SEQ ID NO:4

or SEQ ID NO:6 over the entire length of SEQ ID NO:2; SEQ ID NO:4 or SEQ ID NO:6 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

9. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2; SEQ ID NO:4 or SEQ ID NO:6 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.

10. An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1, 3 or 5 over the entire length of SEQ ID NO:1, 3 or 5 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.

11. The isolated polynucleotide as claimed in any one of claims 7 to 10 in which the identity is at least 95% to SEQ ID NO:1,3 or 5.

12. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2; SEQ ID NO:4 or SEQ ID NO:6.

13. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1; SEQ ID NO:3 or SEQ ID NO:5.

14. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2; SEQ ID NO:4 or SEQ ID NO:6 obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1; SEQ ID NO:3 or SEQ ID NO:5 or a fragment thereof.

15. An expression vector or a recombinant live microorganism comprising an isolated polynucleotide according to any one of claims 7 - 14.

16. A host cell comprising the expression vector of claim 15 or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:4 and SEQ ID NO:6.
17. A process for producing a polypeptide of claims 1 to 6 comprising culturing a host cell of claim 16 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.
18. A process for expressing a polynucleotide of any one of claims 7 – 14 comprising transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.
19. A vaccine composition comprising an effective amount of the polypeptide of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.
20. A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 7 to 14 and a pharmaceutically effective carrier.
21. The vaccine composition according to either one of claims 19 or 20 wherein said composition comprises at least one other *Moraxella catarrhalis* antigen.
22. An antibody immunospecific for the polypeptide or immunological fragment as claimed in any one of claims 1 to 6.
23. A method of diagnosing a *Moraxella catarrhalis* infection, comprising identifying a polypeptide as claimed in any one of claims 1 - 6, or an antibody that is immunospecific

for said polypeptide, present within a biological sample from an animal suspected of having such an infection.

24. Use of a composition comprising an immunologically effective amount of a polypeptide as claimed in any one of claims 1 – 6 in the preparation of a medicament for use in generating an immune response in an animal.

25. Use of a composition comprising an immunologically effective amount of a polynucleotide as claimed in any one of claims 7 - 14 in the preparation of a medicament for use in generating an immune response in an animal.

26. A therapeutic composition useful in treating humans with *Moraxella catarrhalis* disease comprising at least one antibody directed against the polypeptide of claims 1 – 6 and a suitable pharmaceutical carrier.

SEQUENCE LISTING

<110> SmithKline Beecham Biologicals S.A.

<120> Novel Compounds

<130> BM45414

<160> 6

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1035

<212> DNA

<213> *Moraxella catarrhalis*

<400> 1

atgaaagcac	aattttacaac	cctaaaagtc	atcggcggac	tattttgtagg	tggcatgatg	60
ctaaatgcac	atgcagcacc	tgaattatat	ggttacgcaa	atcttgctcgt	ttctgctaata	120
cataaaaaaa	caaccaacaa	gacaaccaat	gtcagtacat	caacaacaga	ccgcccctat	180
ctgtatagca	gcggatcacg	cattggcctt	agaggggtctg	aaaagttaaa	tgatgattat	240
gaggttttgt	acaagttgga	gtaccgtcta	gaaaatgatg	gtgatttacg	caatgaaaaa	300
atcaagcagc	cagatggtac	tgaaaagact	gttgctaaaa	cacgcaattt	tgaggctcgt	360
gattcatgga	ttggcgtgaa	gcataaaaaa	tatggtacca	tcaaggcggg	tcgtatggtg	420
tctttggatc	catatgtgcg	ttatactgcc	tattttggcgt	caggcgtaga	tgggggtgcgt	480
accaataata	ccattgcata	cgaatcacca	aaaatcaaag	atgtagtatt	tcaggcgatg	540
tacatcttag	atgaaaataa	agagacagat	accattgata	gtgatgggta	ttcattgctt	600
gtcaagaaaa	acacagatac	atataatgtt	ggtgcagctt	atgcctattt	tggtaaagca	660
aaaacctctt	atggcaagat	taactatact	gcgcgtgtga	caggtaatta	taaaattaat	720
gaggattata	aagtaggtgg	tatctatcag	catgtcggct	atgccaatga	cgacagtgcc	780
aaaaataata	cagaacaagc	tgttggcgtg	gctttgcagc	attttaaaga	caaattggact	840
cataccgcac	acatgaatct	tgtgaataat	cctagtggga	aaaagggcga	tgggtttgag	900
ctgatcggag	caattgaccg	tgatatttct	aaaaatgtct	ctgcaggcat	ggatatcacc	960
tatggttaact	ttaactacgc	aacagaaaaa	gaatcttaca	tcaacccaac	tatctatgcg	1020
actgtatatatt	tttaa					1035

<210> 2

<211> 344

<212> PRT

<213> *Moraxella catarrhalis*

<400> 2

Met	Lys	Ala	Gln	Phe	Thr	Thr	Leu	Lys	Val	Ile	Gly	Gly	Leu	Phe	Val
1			5					10					15		
Gly	Gly	Met	Met	Leu	Asn	Ala	His	Ala	Ala	Pro	Glu	Leu	Tyr	Gly	Tyr
		20					25					30			
Ala	Asn	Leu	Val	Val	Ser	Ala	Asn	His	Lys	Lys	Thr	Thr	Asn	Lys	Thr
	35					40					45				
Thr	Asn	Val	Ser	Thr	Ser	Thr	Thr	Asp	Arg	Pro	Tyr	Leu	Tyr	Ser	Ser
	50				55					60					
Gly	Ser	Arg	Ile	Gly	Leu	Arg	Gly	Ser	Glu	Lys	Leu	Asn	Asp	Asp	Tyr
65			70				75					80			
Glu	Val	Leu	Tyr	Lys	Leu	Glu	Tyr	Arg	Leu	Glu	Asn	Asp	Gly	Asp	Leu

[illegible]

<210> 3

<211> 2037

<212> DNA

<213> Moraxella catarrhalis

<400> 3

atgcggtttta	taccttttgc	tgtaactctt	ttatctttta	ctggctcctc	catcttttct	60
gtggccaaag	ctcagattgc	accagaccca	accaaagcaa	atctttctgc	aataaccgat	120
gatcgctcgtc	aggcggctct	tgcacattta	gcaagacaag	atttggcagc	aacagatgac	180
gacatgggtg	tcgatatcaa	tcaaaccaat	atcaaccagc	caaattggca	agatgacaag	240
aatggcgatt	catgtttttt	ggttgatgag	attgactttg	tgattgaggg	tggagaagat	300
aaacatattc	taggtatgac	gccgagcaat	ttacgcagct	tgctatcgcc	cctggtggac	360
cggacaaagc	caacatatgc	tcttaattcac	tgcactcaaca	atcacaacct	atctttaatt	420
gtagatattg	cccataatga	attactaaag	cgtggttatt	taactagcag	tattagcatt	480
gaagagcagg	atztatcaac	taaaaaactc	actttaacag	tccatgctgg	caaggtgaaa	540
aagggtgatat	tggccgatgc	tagcaaaacg	ccaacttatg	tcaaagccgc	cattcctctt	600
aagttcaatc	aagcctttcg	tctgtcatat	ttagaacaag	gtctagataa	tttaaaacgc	660
atcgatccaa	cggcaaccgt	gcagattata	ccaagcagct	ccagtaatgt	cgccaatgat	720
attgacatta	acaccacaaa	ccttggtttt	agtgatttac	tcattaggat	ggaccgcagt	780
caaagcgtg	tatttggcat	taatattgat	aacagtttat	ccaaagatta	tggcaattat	840
ctgattttctg	ctaatgttcg	tgctaaacaac	ctcatgcac	ttaacgatga	atggaatcct	900
tctgccaaact	atccattggc	gcgcctgatt	gacgctgccc	aaaatgatct	tggggttcag	960


```

gtgggcaagg ataggcaggt taattatcac gcttccttga ctattcctta tggattgtat 1020
aaattttctg ccacacacag ccaccaccaa taccagcaat ttcttgaagg gcttcatgcg 1080
cccttgactt atcatggcac cagcaagaca agctcaattg gattgtctcg tttattgcac 1140
cgtgatggca atcaaaagac tgaagggtat ataaaggtta atcacaaacg aagcagtaat 1200
tatattgatg atgttaatct tgaagtgcga aaccgccgca caacaggata taacattggc 1260
atcactcatc agcatcatct tcaccaaggt gggtatttgt atgccaaactt ggattataag 1320
caaggaacag gggcactaaa agcaaagcct gcacctgaag agcatattta tgatgctttt 1380
gggcgacaac taccagtgga gggttttgca aaagcaccaa tttggtcact atacaccagt 1440
ttccaaaagc catttgtgtt aaacaaccca aatgatactg aacaagcgca agataaagca 1500
acagcaaata aacccattta cacatccatt cctctcactt atactgctag attacaagcc 1560
caatatgcca aacaacttcc tgtaccatct gatttattct atttgggtgg cagatatagc 1620
attaaaggca ttaaagaggg aaattattta tcaggagaac atggccttag cctatcccaa 1680
gaacttgctt ggcaattgcc attacagaat cttaatcagc acttttagtac aaatgcaaac 1740
agcgccagct tgtatgcaag tattgatcaa ggctatgcct atggaaaaaa cactcttaat 1800
aatcaacgcc atatcttggc tggagcgggt ggtatgaggt attattttca aggcagtcaa 1860
gatccaagaa ttcaagaaac acaaaatggc ttgactcatt tcaaagaatc aaatacttat 1920
ctaaataaca caccaaccac agctcatttg gatataattca ttggaaaagg aattaagacg 1980
cctgaattta tgaagaaaga aaccgtcgtg ggtgtgagtg ccagcattga gttttaa 2037

```

<210> 4

<211> 678

<212> PRT

<213> *Moraxella catarrhalis*

<400> 4

```

Met Arg Phe Ile Pro Phe Ala Val Thr Leu Leu Ser Phe Thr Gly Ser
1          5          10          15
Ser Ile Phe Ser Val Ala Lys Ala Gln Ile Ala Pro Asp Pro Thr Lys
20          25          30
Ala Asn Leu Ser Ala Ile Thr Asp Arg Arg Gln Ala Ala Leu Ala
35          40          45
His Leu Ala Arg Gln Asp Leu Ala Ala Thr Asp Asp Asp Met Gly Val
50          55          60
Asp Ile Asn Gln Thr Asn Ile Asn Gln Pro Asn Trp Gln Asp Asp Lys
65          70          75          80
Asn Gly Asp Ser Cys Phe Leu Val Asp Glu Ile Asp Phe Val Ile Glu
85          90          95
Gly Gly Glu Asp Lys His Ile Leu Gly Met Thr Pro Ser Asn Leu Arg
100          105          110
Ser Leu Leu Ser Pro Leu Leu Asp Arg Thr Lys Pro Thr Tyr Ala Leu
115          120          125
Asn His Cys Ile Asn Asn His Asn Leu Ser Leu Ile Val Asp Ile Ala
130          135          140
His Asn Glu Leu Leu Lys Arg Gly Tyr Leu Thr Ser Ser Ile Ser Ile
145          150          155          160
Glu Glu Gln Asp Leu Ser Thr Lys Lys Leu Thr Leu Thr Val His Ala
165          170          175
Gly Lys Val Lys Lys Val Ile Leu Ala Asp Ala Ser Lys Thr Pro Thr
180          185          190
Tyr Val Lys Ala Ala Ile Pro Leu Lys Phe Asn Gln Ala Phe Arg Leu
195          200          205
Ser Tyr Leu Glu Gln Gly Leu Asp Asn Leu Lys Arg Ile Asp Pro Thr
210          215          220
Ala Thr Val Gln Ile Ile Pro Ser Ser Ser Ser Asn Val Ala Asn Asp
225          230          235          240
Ile Asp Ile Asn Thr Thr Asn Leu Gly Phe Ser Asp Leu Leu Ile Arg
245          250          255
M t Asp Arg Ser Gln Ser Ala Val Phe Gly Ile Asn Ile Asp Asn Ser

```


260 265 270
 Leu Ser Lys Asp Tyr Gly Asn Tyr Leu Ile Ser Ala Asn Val Arg Ala
 275 280 285
 Asn Asn Leu Met His Leu Asn Asp Glu Trp Asn Leu Ser Ala Asn Tyr
 290 295 300
 Pro Leu Ala Arg Leu Ile Asp Ala Ala Gln Asn Asp Leu Gly Val Gln
 305 310 315 320
 Val Gly Lys Asp Arg Gln Val Asn Tyr His Ala Ser Leu Thr Ile Pro
 325 330 335
 Tyr Gly Leu Tyr Lys Phe Ser Ala Thr His Ser His His Gln Tyr Gln
 340 345 350
 Gln Phe Leu Glu Gly Leu His Ala Pro Leu Thr Tyr His Gly Thr Ser
 355 360 365
 Lys Thr Ser Ser Ile Gly Leu Ser Arg Leu Leu His Arg Asp Gly Asn
 370 375 380
 Gln Lys Thr Glu Gly Tyr Ile Lys Val Asn His Lys Arg Ser Ser Asn
 385 390 395 400
 Tyr Ile Asp Asp Val Asn Leu Glu Val Gln Asn Arg Arg Thr Thr Gly
 405 410 415
 Tyr Asn Ile Gly Ile Thr His Gln His His Leu His Gln Gly Gly Tyr
 420 425 430
 Leu Tyr Ala Asn Leu Asp Tyr Lys Gln Gly Thr Gly Ala Leu Lys Ala
 435 440 445
 Lys Pro Ala Pro Glu Glu His Ile Tyr Asp Ala Phe Gly Arg Gln Leu
 450 455 460
 Pro Ser Glu Gly Phe Ala Lys Ala Pro Ile Trp Ser Leu Tyr Thr Ser
 465 470 475 480
 Phe Gln Lys Pro Phe Val Leu Asn Asn Pro Asn Asp Thr Glu Gln Ala
 485 490 495
 Gln Asp Lys Ala Thr Ala Asn Lys Pro Ile Tyr Thr Ser Ile Pro Leu
 500 505 510
 Thr Tyr Thr Ala Arg Leu Gln Ala Gln Tyr Ala Lys Gln Leu Pro Val
 515 520 525
 Pro Ser Asp Leu Phe Tyr Leu Gly Gly Arg Tyr Ser Ile Lys Gly Ile
 530 535 540
 Lys Glu Gly Asn Tyr Leu Ser Gly Glu His Gly Phe Ser Leu Ser Gln
 545 550 555 560
 Glu Leu Ala Trp Gln Leu Pro Leu Gln Asn Leu Asn Gln His Phe Ser
 565 570 575
 Thr Asn Ala Asn Ser Ala Gln Leu Tyr Ala Ser Ile Asp Gln Gly Tyr
 580 585 590
 Ala Tyr Gly Lys Asn Thr Leu Asn Asn Gln Arg His Ile Leu Ala Gly
 595 600 605
 Ala Val Gly Met Arg Tyr Tyr Phe Gln Gly Ser Gln Asp Pro Arg Ile
 610 615 620
 Gln Glu Thr Gln Asn Gly Leu Thr His Phe Lys Glu Ser Asn Thr Tyr
 625 630 635 640
 Leu Asn Asn Thr Pro Thr Thr Ala His Leu Asp Ile Phe Ile Gly Lys
 645 650 655
 Gly Ile Lys Thr Pro Glu Phe Met Lys Lys Glu Thr Val Val Gly Val
 660 665 670
 Ser Ala Ser Ile Glu Phe
 675

<210> 5
 <211> 1410
 <212> DNA
 <213> *Moraxella catarrhalis*

<400> 5
 atgaaaatgc cctattttttt. gcttttggga ttattgttag tacagcaggc tgatgctgat 60
 tatagcttgc ttgatgccca aaaacagctc atgagcagca gccctgccat ccaagcaagt 120
 catgccttgt atcaagctga tgtcttataa gcagaatcat tacaaaaatt acactatcct 180
 aggatatcgc tcaatgcaca cgcctttgta ctgcaacaaa acagcagcat acccttagat 240
 catatcaaag agcagaccgc ccagcacatt aacacccatt ttgaccatcg ctttggcagt 300
 gcccccgatg gtctgttggga tgctttgcac aacagcacc aaaccgccct tgaccgcctg 360
 cctgaccatc aagatgtcaa gttacgccat gatggcatta ccccaaacat taccgccacg 420
 ataccatctc atacaggtgg cttaatcagc agcaccaaaa atatcgccaa tctacaagca 480
 cagcgtggta aatttggatt acaagaacgc atctctttgg caaaacttaa tttgattcgc 540
 cattatttta atgtgcaatt acaaaagcag ctgaccgaca cacaacaaaa catgcttagt 600
 gccatgcagt tacatgtaga taatgcttat aaattagaac agcaagggtt tatcagtcgt 660
 ggacagcgta tgcaatttga agtggcacgc aatcaggtac aaagactgta tcaaagcacc 720
 caaaatcagc accaaaacag ctttatgaa cttgtgttt tgcttgggtt gccccacatt 780
 gaaccgctaa gcacaccgct gtttatcaac acccagcatc gcccgaattg gcaagcatta 840
 ctcaaagact cccaaaatac accattaaat caaaagctaa aaaccgacat tttgcttgcc 900
 gatgaaaata tcgccctaag acaatccacc aaaaaaccaa aaattgccgc tgtggctcgt 960
 tataccttag atgataagcc tgattgggtt gcagggtgtg cggtttctta caacctattc 1020
 ttgggcattg accgtgataa gcagattggg gcagcacacc tacaaaaaca agcagcccaa 1080
 ttgggtcatg aacaagtcaa tgaacacatc acaaccacca tgcacaccgc ttatggcgag 1140
 atgggtgctg cacaaaaaac ccacgcccta ctacaacaaa atcgtcaagc cgccaaagaa 1200
 aatttgcgta tccagacgct gtcttttcaa gaagggttg ggacgggtggc aggtgtggtt 1260
 gatgccccaa gtgctttatc acagattgac agcgaaccgc ctctaaatgc gtatcgctac 1320
 cttttggcac tggcgacgct gttgcattac acagggacaa ttgatgactt tgatgattat 1380
 ttgtctttgg atgatgtca taaactgtga 1410

<210> 6
 <211> 469
 <212> PRT
 <213> *Moraxella catarrhalis*

<400> 6
 Met Lys Met Pro Tyr Phe Leu Leu Leu Gly Leu Leu Leu Val Gln Gln
 1 5 10 15
 Ala Asp Ala Asp Tyr Ser Leu Leu Asp Ala Gln Lys Gln Leu Met Ser
 20 25 30
 Ser Ser Pro Ala Ile Gln Ala Ser His Ala Leu Tyr Gln Ala Asp Val
 35 40 45
 Leu Gln Ala Glu Ser Leu Gln Lys Leu His Tyr Pro Arg Ile Ser Leu
 50 55 60
 Asn Ala His Ala Phe Val Leu Gln Gln Asn Ser Ser Ile Pro Leu Asp
 65 70 75 80
 His Ile Lys Glu Gln Thr Ala Gln His Ile Asn Thr His Phe Asp His
 85 90 95
 Arg Phe Gly Ser Ala Pro Asp Gly Leu Leu Asp Ala Leu His Asn Ser
 100 105 110
 Thr Gln Thr Ala Leu Asp Arg Leu Pro Asp His Gln Asp Val Lys Leu
 115 120 125
 Arg His Asp Gly Ile Thr Pro Asn Ile Thr Ala Thr Ile Pro Ile Tyr
 130 135 140
 Thr Gly Gly Leu Ile Ser Ser Thr Lys Asn Ile Ala Asn Leu Gln Ala
 145 150 155 160
 Gln Arg Gly Lys Phe Gly Leu Gln Glu Arg Ile Ser Leu Ala Lys Leu


```

      165      170      175
Asn Leu Ile Arg His Tyr Phe Asn Val Gln Leu Gln Lys Gln Leu Thr
      180      185      190
Asp Thr Gln Gln Asn Met Leu Ser Ala Met Gln Leu His Val Asp Asn
      195      200      205
Ala Tyr Lys Leu Glu Gln Gln Gly Phe Ile Ser Arg Gly Gln Arg Met
      210      215      220
Gln Phe Glu Val Ala Arg Asn Gln Val Gln Arg Leu Tyr Gln Ser Thr
      225      230      235
Gln Asn Gln His Gln Asn Ser Ile Tyr Glu Leu Ala Val Leu Leu Gly
      245      250      255
Leu Pro His Ile Glu Pro Leu Ser Thr Pro Leu Phe Ile Asn Thr Gln
      260      265      270
His Arg Pro Asn Trp Gln Ala Leu Leu Lys Asp Ser Gln Asn Thr Pro
      275      280      285
Leu Asn Gln Lys Leu Lys Thr Asp Ile Leu Leu Ala Asp Glu Asn Ile
      290      295      300
Ala Leu Arg Gln Ser Thr Lys Lys Pro Lys Ile Ala Ala Val Ala Arg
      305      310      315
Tyr Thr Leu Asp Asp Lys Pro Asp Trp Phe Ala Gly Val Ala Val Ser
      325      330      335
Tyr Asn Leu Phe Leu Gly Ile Asp Arg Asp Lys Gln Ile Gly Ala Ala
      340      345      350
His Leu Gln Lys Gln Ala Ala Gln Leu Gly His Glu Gln Val Asn Glu
      355      360      365
His Ile Thr Thr Thr Met His Thr Ala Tyr Gly Glu Met Val Leu Ala
      370      375      380
Gln Lys Thr His Ala Leu Leu Gln Gln Asn Arg Gln Ala Ala Lys Glu
      385      390      395
Asn Leu Arg Ile Gln Thr Leu Ser Phe Gln Glu Gly Phe Gly Thr Val
      405      410      415
Ala Gly Val Val Asp Ala Gln Ser Ala Leu Ser Gln Ile Asp Ser Glu
      420      425      430
Thr Ala Leu Asn Ala Tyr Arg Tyr Leu Leu Ala Leu Ala Thr Leu Leu
      435      440      445
His Tyr Thr Gly Thr Ile Asp Asp Phe Asp Asp Tyr Leu Ser Leu Asp
      450      455      460
Asp Ala His Lys Leu
465

```



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19862 A3

(51) International Patent Classification⁷: C07K 14/22,
16/12, C12N 1/21, 15/31, A61K 38/16, 39/40, G01N
33/569

(74) Agent: PRIVETT, Kathryn Louise; SmithKline
Beecham, Two New Horizons Court, Brentford, Middlesex
TW8 9EP (GB).

(21) International Application Number: PCT/EP00/09034

(22) International Filing Date:
14 September 2000 (14.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9921694.7 14 September 1999 (14.09.1999) GB
9921693.9 14 September 1999 (14.09.1999) GB
9922829.8 25 September 1999 (25.09.1999) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM BIOLOGICALS S.A.
[BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(88) Date of publication of the international search report:
4 October 2001

(72) Inventor; and
(75) Inventor/Applicant (*for US only*): THONNARD, Joelle
[BE/BE]; SmithKline Beecham Biologicals s.a., Rue de
L'Institut 89, B-1330 Rixensart (BE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYPEPTIDES FROM MORAXELLA (BRANHAMELLA) CATARRHALIS

(57) Abstract: The invention provides BASB129, BASB130 and BASB131 polypeptides and polynucleotides encoding BASB129, BASB130 and BASB131 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

WO 01/19862 A3





1

2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09034

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07K14/22 C07K16/12 C12N1/21 C12N15/31 A61K38/16
 A61K39/40 G01N33/569

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 41731 A (ANTEX BIOLOGICS, INC.) 13 November 1997 (1997-11-13) the whole document ---	1-26
A	WO 98 06851 A (BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEM) 19 February 1998 (1998-02-19) the whole document --- -/--	1-26

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 March 2001

Date of mailing of the international search report

02. 5. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Fuchs, U



1

2

3

4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09034

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EMBL database, Heidelberg, FRG Trembl accession number Q99116 1 November 1996 MAIDEN, M.C.J. ET AL.: "MAJOR OUTER MEMBRANE PROTEIN P.IA (PROTEIN IA) (PIA) (FRAGMENT)" XP002162771 the whole document	1-26
A	-& MAIDEN, M.C.J. ET AL.: "Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis" MOLECULAR MICROBIOLOGY, vol. 5, no. 3, March 1991 (1991-03), pages 727-736, XP000926232 the whole document -----	1-26



1

2

3

4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 00/09034

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-26 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



1

2

3

4

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-26 partially

An isolated polypeptide comprising an amino acid sequence which has at least 85% identity to the amino acid sequence SEQ ID NO: 2 over the entire length, an isolated polypeptide of SEQ ID NO: 2, an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 85% identity to the amino acid sequence SEQ ID NO: 2 over the entire length or a nucleotide sequence complementary to said polynucleotide, an isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO: 2 over the entire coding region or a nucleotide sequence complementary to said polynucleotide, an isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO: 1 over the entire length or a nucleotide sequence complementary to said polynucleotide, an isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO: 2, an isolated polynucleotide comprising the polynucleotide of SEQ ID NO: 1, an expression vector or a recombinant live microorganism comprising said polynucleotide, a process for producing said polypeptide, a vaccine composition comprising said polypeptide or said polynucleotide, an antibody immunospecific for said polypeptide, a method of diagnosing a M. catarrhalis infection involving said polypeptide or said antibody, use of a composition comprising said polypeptide or said polynucleotide in the preparation of a medicament for immunization, a therapeutic composition comprising at least one antibody directed against said polypeptide;

2. Claims: 1-26 partially

Idem as subject 1 but limited to SEQ ID NOS: 3 and 4;

3. Claims: 1-26 partially

Idem as subject 1 but limited to SEQ ID NOS: 5 and 6.



r

u

r

h

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/09034

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9741731 A	13-11-1997	AU 723528 B	31-08-2000
		AU 3118097 A	26-11-1997
		BG 102983 A	31-05-2000
		BR 9711090 A	17-08-1999
		CZ 9803524 A	16-06-1999
		EP 0900025 A	10-03-1999
		JP 2000510696 T	22-08-2000
		NO 985113 A	28-12-1998
		PL 330935 A	07-06-1999
		SK 150998 A	07-05-1999
		US 6214981 B	10-04-2001
WO 9806851 A	19-02-1998	AU 4150097 A	06-03-1998
		EP 0920513 A	09-06-1999

